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Apicomplexa parasites, including Toxoplasma gondii and Plasmodium falciparum, contain a 
secondary endosymbiosis-derived plastid like organ, called apicoplast, which is an anabolic hub. 
This apicoplast is fueled by phosphate translocator (APT), which transport phosphorylated sugar 
molecules in exchange of inorganic phosphate. Disruption of APT in T. gondii was found to be 
lethal for parasite.  Beside this, its’s plastidic nature and location in apicoplast, made it an ideal 
drug target. 
In this study two homology models of TgAPT were used for predicting putative inhibitors 
against this protein by combining ligand-based virtual screening (LBVS) and structure-based 
virtual screening (SBVS) approaches. Before doing the actual screening, a homology model of 
another APT, called PfoTPT from P. falciparum was generated to compare the binding pocket 
and the binding of known ligands by docking. The binding pocket of TgAPT was also compared 
with other plastidic phosphate translocator classes. The comparison revealed that there was only 
one amino acid different between two APTs, but several differences between the APTs and pPT 
classes and these differences are assumed to contribute to differences in substrate recognition 
and binding. Then, known substrates, non-substrates and inhibitors were docked in two TgAPT 
models and PfoTPT model. The non-substrates are those which are not usually transported, nor 
they inhibit the transport process. The PfoTPT model did not show good result in terms of 
scoring and rank ordering of compounds. Of the two TgAPT models, TgAPT_5y79 showed 
comparatively better result, so induced fit docking (IFD) was done in this model with 3- 
phosphoglyceric acid (3-PGA), phosphoenol pyruvate (PEP), pyridoxal-5-phosphate (PLP) and 
2,4,6- trinitrobenzene sulfonate (TNBS) for generating better conformation. Then one of the 
poses generated with 3-PGA IFD was selected for the SBVS approach.  
In VS approach, analogs of substrates and inhibitors were retrieved from PubChem database and 
docked into the IFD generated pose. From this docking, 318 compounds were sorted from 
different analog groups and compounds of each group were clustered by hierarchical clustering. 
Finally, 29 compounds were predicted as putative inhibitor of TgAPT based on the docking 
score and their interaction with the protein. These compounds will be tested in vitro for the 
inhibition potential. 
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1.1 Apicomplexa parasites 
Apicomplexa is a large phylum that consists of single-celled obligate intracellular parasitic 
protozoans. The defining characteristic of the members of this phylum is a group of organelles 
found in one end of the cell called apical complex. This complex, which gives the name 
apicomplexa, plays a crucial role during invasion of host cell (Katris et al., 2014).  
This phylum includes a large spectrum of species, more than 6000 of which are named and even 
more than 6000 that are unnamed (Adl et al., 2007). Because of this versatility there is a wide 
range of hosts of this protist group including invertebrates, reptiles, amphibians, and mammals 
including humans (Duszynski, Wilson, J. Upton, & D. Levine, 1999). Two of the most important 
species are Plasmodium falciparum (P. falciparum) and Toxoplasma gondii (T. gondii), the 
causative agent of malaria and toxoplasmosis (Seeber & Steinfelder, 2016). The protein of 
interest in this study is from T. gondii. 
1.2 Toxoplasma gondii  
T. gondii is an opportunistic pathogen that is capable of infecting warm-blooded animals (Innes, 
2010). In a statistic it was seen that the infection rate of T. gondii in the world population is up to 
50% without showing any symptoms (Flegr, Prandota, Sovičková, & Israili, 2014). Even in 
Norway this parasite is widespread, especially in cats and sheep (Institute, 2016). Although in 
humans this infection is not apparently harmful, but chronic infection for lifetime can occur. 
There is also a chance of formation of cysts in host’s brain, skeletal muscle, heart and other vital 
organs. Additionally, T. gondii infection can lead to retinitis retinae, encephalitis and even death 
in immunodeficient patient (Jensen et al., 2015).  
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Figure 1. 1: Different organelles of T. gondii (Black & Boothroyd, 2000) 
T. gondii is also considered as a model organism for studying Apicomplexan biology because of 
the well-established methodologies to study this organism (Kim & Weiss, 2004). The studies 
have shown some unique characteristics and organelles in more detail. For example, the 
apicoplast was identified as a whole organelle by in-situ hybridization studies in T. gondii, even 
though the presence was noticed before (McFadden, Reith, Munholland, & Lang-Unnasch, 
1996). Later, this organelle got more attention for being the site of metabolic pathways different 
from the vertebrate hosts and these pathways can be a potential target for new chemotherapeutics 
(Seeber, Feagin, & Parsons, 2014).  
1.3 The apicoplast 
The apicoplast is a vestigial plastid found in species of Apicomplexa. It has evolved by 
secondary endosymbiosis, which is indicated by the presence of three or four membranes 
surrounding it (Gould, Waller, & McFadden, 2008). These membranes represent their origin 
from different sources, for example the outer membrane is similar to the host endomembrane 
system, the second membrane resembles the plasma membrane of the second endosymbiont and 
the third and fourth correspond to the envelope membranes of the primary plastid (Roos, 
Kissinger, Fast, & Keeling, 2001), 2001). There is now clear-cut evidence suggesting that the 
second endosymbiont was a red alga (Liting Lim & McFadden, 2010). In contrast to the 
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photosynthetic algal plastid, the apicoplast is non-photosynthetic. So, the question comes why 
are the parasites investing energy on maintaining this organelle? 
To answer this question, the function of plastids not involved in photosynthesis was looked at. It 
turned out that non-photosynthetic plastids are involved in the biosynthesis of various 
metabolites and from this, the conclusion was drawn that apicoplasts work in a similar manner in 
the Apicomplexa parasites. The theory behind that was that earlier in the symbiosis event, when 
the endosymbiont still had full photosynthetic capacity, the host started to make itself dependent 
on the symbiont for various metabolites which they got without or by the expense of little 
energy. Another probable reason was that, by this manner they could manage to accumulate 
biosynthesis redundancy. So, later despite the loss of photosynthetic capacity, the hosts are 
maintaining this organelle for the metabolites produced in the apicoplasts (Striepen, 2011). Now, 
the next question comes, what is the actual function of apicoplast? 
Initially, this question was not answered by biochemical approaches, but rather by bioinformatic 
and genomic approaches. Genome sequence of many species including Plasmodium, 
Toxoplasma and Cryptosporidium have fueled this type of studies (Striepen, 2011). From these 
studies, about 500 apicoplast proteins were predicted (Ralph et al., 2004) and three major 
anabolic pathways (fatty acid synthesis, isoprenoid synthesis and part of the haem synthesis 
pathway), usually found in chloroplasts, were also found in apicoplasts of Plasmodium and 
Toxoplasma (Seeber & Soldati-Favre, 2010). Interestingly, there are differences in metabolic 
pathways within the species of Apicomplexa (Figure 1.2). This indicates that the apicoplast 
function is not rigid, rather the metabolites acquisition by the host from the apicoplast depend on 
the specific tissue or cell the parasites occupy (Striepen, 2011) 
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Figure 1. 2: Evolutionary relationship and adoption of biosynthetic pathways among different members of 
Apicomplexa (Striepen, 2011) 
1.4 Apicoplast metabolism and potential drug targets 
Anabolic pathways residing in apicoplasts are of divergent evolutionary origin from those in 
human cells, so have different biochemical mechanisms. These differences are making molecules 
involved in those pathways potential drug targets. An overview of the apicoplast metabolism is 




Figure 1. 3: Overview of apicoplast metabolism. Three pathways (FASII, DOXP and haem) are shown here. 
FasII and DOXP directly depend upon the imported sugars from the cytoplasm. The haem synthesis is 
distributed in apicoplasts and mitochondria. ALA, aminolevulinic acid; Glc, glucose; PEP, 
phosphoenolpyruvate; suc-CoA, succinyl-CoA; UROIII, uroporphyrinogen-III. (Striepen, 2011) 
1.4.1 Fatty Acid Biosynthesis 
Fatty acids are one of the fundamental components in any living cell because of their role as 
membrane building blocks, energy storage molecules, precursors for second messenger and co-
factors. In comparison to other organisms, Apicomplexans are much more in need of fatty acids 
because of their additional membrane-bound organelles like micronemes, rhoptries, dense 
granules, pellicular complex, the apicoplast and the growing parasitophorous vacuole membrane 
beside the regular organelles like nucleus, endoplasmic reticulum, golgi body etc. (Bisanz et al., 
2006; Charron & Sibley, 2002; Coppens & Vielemeyer, 2005). Fatty acids are generated in two 
different ways by living organisms. The FASI pathway, which is used by eukaryotic cells, 
combine all enzymatic steps in one multifunctional protein and produce Palmitate (C16) as end 
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product. On the other hand, the FASII pathway, where individual steps are carried out by 
separate protein entities, generates C8 and longer fatty acids (Seeber & Soldati-Favre, 2010). 
Apicoplasts use the second pathway. Interestingly, Theileria sp. and B. bovis lack this machinery 
for fatty acid synthesis and they acquire fatty acids from the host (Seeber & Soldati-Favre, 
2010).  
Initially, molecules involved in this pathway were thought to be potential targets for drugs 
because of its essence for the survival of parasites as proved in T. gondii (Mazumdar, H Wilson, 
Masek, A Hunter, & Striepen, 2006). The FASII enzyme FabI inhibitor Triclosan was tested and 
found to be efficient against Plasmodium and Toxoplasma (Striepen, 2011). But in other studies, 
it was found that Triclosan is also efficient in a FabI mutant as well as in Theileria and B. bovis 
(Seeber & Soldati-Favre, 2010), which indicates Triclosan off-target activity and hence negates 
the possibility of using Triclosan as drug against these parasites.  
1.4.2 Isoprenoid Biosynthesis 
Isoprenoids are a diverse group of nuclear compounds with more than 23000 known structures 
(Holstein & Hohl, 2004). The diversity represents their diverse roles in biological activities, such 
as cell signaling, modification of proteins and tRNAS and synthesis of Ubiquinone (Seeber & 
Soldati-Favre, 2010). The starting compounds of this pathway are isopentenyl diphosphate and 
its isomer dimethylallyl diphosphate, which can be achieved in two ways, which are the 1-deoxy-
D-xylulose-5-phosphate (DOXP) pathway, also known as methylerythritriol phosphate (MEP) 
pathway, and the mevalonate pathway (MEV) (Eisenreich, Bacher, Arigoni, & Rohdich, 2004; 
Lichtenthaler, 1999; Rohmer, 1999). The former one is generally used by eubacteria and plants 
and the latter one is used by archaebacteria and eukaryotes. Interestingly, the majority of plants 
and a few bacteria possess both pathways (Kirby & Keasling, 2009; Rohmer, 1999).  
Apicomplexans only possess the entire set of genes coding for the bacterial DOXP pathway 
(Clastre et al., 2007; Grauvogel, Reece, Brinkmann, & Petersen, 2007). As these genes are not 
found in human cells, the enzymes of this pathway are potential drug targets. From this idea the 
antibiotic fosmidomycin (Fos), which is a DOXP reductoisomerase (Dxr) inhibitor, was tested 
against P. falciparum and found to inhibit the growth of the malaria parasite in blood stages 
(Jomaa et al., 1999; Oyakhirome et al., 2007). But this compound was found to not inhibit the 
growth of T. gondii despite having structural and binding site similarities of TgDxr with PfDxr. 
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One of the reasons might be the poor uptake of the drug by T. gondii infected cell (Seeber & 
Soldati-Favre, 2010).  
1.4.3 Haem biosynthesis 
Haem is well known for its role in binding O2 in hemoglobin as well as co-factor for several 
enzymes. Haem biosynthesis in apicomplexans is unique as it is partly located in mitochondria, 
apicoplasts and cytosol. On the other hand, in animals it is localized in mitochondria and in 
plants in plastids (Heinemann, Jahn, & Jahn, 2008; Layer, Reichelt, Jahn, & Heinz, 2010; Seeber 
& Soldati-Favre, 2010; Tanaka & Tanaka, 2007). This complex sub-cellular localization reflects 
the evolutionary mosaic with its origin from different sources. The potential of this pathway to 
be a pathway for drug interference was tested by using an inhibitor against one of the enzymes of 
this pathway in T. gondii and at high concentration the parasite was killed. But there is a lot to be 
done to elucidate the therapeutic potential of this pathway against these parasites (Striepen, 
2011).  
1.5 Apicoplast Phosphate Translocator 
In the above description, some pathways for drug interference are described, but actually many 
more studies were done and are still being done to find a suitable way of inhibiting the function 
of apicoplasts (Fleige, Limenitakis, & Soldati, 2010; Goodman, Su, & McFadden, 2007; 
Lizundia, Werling, Langsley, & Ralph, 2009; Moreno & Li, 2008). Most of the work is focusing 
on internal processes of apicoplasts, which can be disadvantageous in a sense that if any potential 
inhibitor of any of the pathways is found, that inhibitor must overcome the barrier of four layers 
of membranes to reach to the target. In this case, Apicoplast Phosphate Translocator (APT) 
turned out to be interesting target for therapeutic intervention, which act as a link between the 
apicoplast metabolism and the cytoplasmic metabolism. 
As discussed above, apicomplexa had to feed their apicoplasts with carbon sources, energy and 
reduction equivalents upon loss of photosynthesis. This supply is done by the APTs, which are 
members of a larger family of plastid phosphate translocators (pPT) (Striepen, 2011). These 
proteins act as antiporters and exchange inorganic phosphate for phosphorylated sugars of C3, 
C5 or C6 lengths (Brooks et al., 2010). In higher plants there are different pPTs for translocating 
different substrates, for example the triose phosphate / phosphate translocator (TPT) transports 
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triose phosphate (Knappe, Flügge, & Fischer, 2003). Similarly, phosphoenolpyruvate transporter 
(PPT), xylulose-5-phosphate transporter (XPT) and glucose-6-phosphate transporter (GPT) 
transport phosphoenolpyruvate, xylulose-5-phosphate and glucose-6-phosphate, respectively 
(Eicks, Maurino, Knappe, Flügge, & Fischer, 2002; Fischer et al., 1997; Kammerer et al., 1998). 
In contrast, APTs have wider substrate specificity than the pPTs in higher plants and that may be 
the reason for fewer transporters in apicomplexa. In Plasmodium two PTs were found, which are 
differentially located in the outer and inner membranes of the apicoplast, and that’s why they are 
named PfoTPT and PfiTPT, respectively. But in the periplastid membrane no such protein is 
identified yet, and it is suggested that these two proteins work in tandem to import the sugar into 
the apicoplast (Mullin et al., 2006). On the other hand, Toxoplasma gondii and Theileria spp 
have only one transporter (Fleige, Fischer, Ferguson, Gross, & Bohne, 2007). For T. gondii this 
transporter is called T. gondii apicoplast phosphate translocator (TgAPT) which is located in 
multiple membranes of the apicoplast (Fleige et al., 2007).  
Among the APTs, PfiTPT, PfoTPT and TgAPT have been studied in more detail compared to 
others and their substrate specificities are determined in vitro. These studies revealed that they 
transport triose phosphate, 3-PGA, PEP and Pi, but not glucose-6-P with different substrate 
preference (Brooks et al., 2010; L. Lim, Linka, Mullin, Weber, & McFadden, 2010). These 
substrates enter the apicoplast and then act as precursors for different pathways. Now the 
question comes, how are these proteins different from other subtypes of pPTS and how do they 
accommodate compounds phosphorylated both in C-2 and C-3 in the same binding pocket? To 
answer this question, structural data are required, which is not available so far.  
1.6 Disruption of APT and its consequences 
One of the ways of determining the importance of a protein is to “knock out” the corresponding 
gene and observe the resulting phenotype. This was done for TgAPT and it was found that the 
parasite died rapidly. This death was thought to be linked with deprival of the apicoplast of 
metabolites required for anabolic pathways, specially FASII and isoprenoid biosynthesis (Brooks 
et al., 2010). In another study, mutation of Pb-TPT, which is one of the two APTs in Plasmodium 
berghei caused death of the parasite, while  mutation of other (Pb-PPT) caused defect in the 
growth of the parasite (Banerjee, Jaijyan, Surolia, Singh, & Surolia, 2012). This phenomenon of 
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APT disruption leads to the idea of finding inhibitors against this protein to develop drugs 
against these parasites. 
1.7 Virtual Screening: A Modern Drug Development Tool 
In Late 1980 and early 1990 progress in experimental high throughput screening (HTS) and 
combinatorial chemistry created an excitement among the scientific community about launching 
significant amount of drug to the market. But due to low hit rates and significant costing reduced 
the euphoria (Lahana, 1999). So, it became necessary to develop new methods, which lead to the 
rise of virtual screening (VS). In contrast to HTS, which is mostly technology driven, VS uses 
computer programs to predict the binding of ligands to macromolecular targets like protein, 
DNA or RNA. There are two main approaches for virtual screening: Ligand based virtual 
screening (LBVS) and structure-based virtual screening (SBVS). 
 
 
Figure 1. 4: Overview of virtual screening approaches. (modified from Gillet, 2013) 
1.7.1 Ligand-based virtual screening 
It is assumed that compounds with similar structures tend to have similar biological properties. 
Based on this principal, this approach is using the structures of active ligands for the target 
protein to derive potential active compounds.  
There are several ways to derive structurally similar compound, which include pharmacophore 
mapping, machine learning methods and similarity method (Fig. 1.4). A pharmacophore is a set 
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of structural features responsible for the compound functionality. In pharmacophore-based 
search, such a set is derived from the active compounds of the target protein and then it is used to 
find new compounds with similar features.  
Machine learning methods are using the knowledge of known actives and known inactives to 
predict a model, which is then used to search for new compounds (Gillet, 2013).  
Similarity based method uses active compounds of the target as reference structure and a search 
is done to find similar compounds of the reference structure. There are several ways of 
measuring similarity, which are categorized into two groups: molecular descriptors and similarity 
coefficients (Gillet, 2013). Molecular descriptors include physicochemical properties, two 
dimensional (2D) and three dimensional (3D) properties. Among these methods 2D 
fingerprinting was found to be most effective (Duan, Dixon, Lowrie, & Sherman, 2010). 
Similarity coefficients measure similarity between two sets of molecular descriptors.  
1.7.2 Structure-based virtual screening 
SBVS is an in-silico study of predicting ligands against a known target, whose 3D structure is 
available. This method includes several steps which are given in figure 1.5. In short, the target 
structure is prepared by choosing the binding site, selection of most relevant target structures, 
incorporating receptor flexibility, suitable assignment of protonation states and consideration of 
water molecules in the binding site. Then the ligands are prepared and docked in the target 
structure, ranked in order based on a scoring function, and final best possible hits are selected by 
more careful examination (Lionta, Spyrou, Vassilatis, & Cournia, 2014).  
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Figure 1. 5: Workflow of SBVS (Lionta et al., 2014). 
1.8 3D structure of the target 
3D structure is an essential part for VS, although in very rare case VS can be executed without 
3D structure of DNA or RNA (Klebe, 2006). But, for proteins, it is must and real structure can be 
gained by X-ray crystallography or nuclear magnetic resonance (NMR) methods. Although these 
are most reliable, but it is not always possible to obtain the 3D structure of the desirable protein 
for various reasons. As an alternative molecular modelling can be applied to generate models.  
1.8.1 Molecular modelling 
By definition, molecular modelling is a way of mimicking the behavior of molecules or 
molecular system. Because of its usefulness, it has become popular in various fields to study 3D 
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structures from small molecular system to large biomolecules including proteins. The main 
feature of this method is to generate a description of the atoms of a molecular system and there 
are two main ways for doing that: 1) Molecular mechanics (MM) and 2) Quantum mechanics 
(QM) (Chen & Houk, 1998). 
In the MM approach, each atom of the system is considered as a particle and the interactions are 
describe by spring-like interactions and van der Waals and electrostatic forces (Cannon, 1996). 
The mathematical expression is called ‘Potential Energy Function (Etot)’, which takes into 
account the bonded (Ebonded) and non-bonded (Enon-bonded) atomic interactions. The bonded 
term computes the deviation of bond lengths (b), bond angles (θ) and torsion angles (φ) away 
from equilibrium values (Eq. 1) and non-bonded term describe van der Waals force and 
electrostatic interaction (Eq. 2) (Bordner, 2012).  
 




The first three terms in Eq. 1 represents the energy of bond stretching, angle bending, rotation of 
torsion angle and the last term is used to maintain planarity of peptide bonds and aromatic rings 
in protein structures. In Eq. 2 the first term represents van der Waals energy and the last term 
represents electrostatic energy.  The suffix i, j represents atoms (fig 1.6) (Bordner, 2012) 
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Figure 1. 6: Bonded interaction variables for the bond length (b), bond angle (q), and dihedral angle (f) as 
seen in Eq. 1 (Bordner, 2012).  
This approach is valid for doing energy minimization, energy calculation of specific 
conformation, generating different conformation, identifying best conformation and molecular 
motion.  
In QM, the movement of electrons relative to nucleus are also included, which made it possible 
to derive properties that depend upon the electronic distribution. As a result, this approach has 
higher accuracy of geometry and energy calculation than the MM. The problem with this method 
is that it is time consuming and limited to small molecules (Chen & Houk, 1998). 
1.8.2 Protein modelling 
There are three different ways for constructing 3D models of proteins: 1) Homology modelling, 
2) Threading/ fold recognition and 3) Ab-initio methods.  
Homology modelling is used when the structure of a similar (homologues) protein (template) to 
the target is available. Using the structure of the template, the structure of the target protein can 
be constructed (Krieger, B Nabuurs, & Vriend, 2003).  
The next method is threading, which is applicable when there is no detailed structure of a 
specific homologue available, but only homologous proteins with low similarity with the target. 
In this case the sequence of the unknown target protein is compared with available structures 
with low similarity in the PDB database and then the best fitting structure is selected (Forster, 
2002).  
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The ab-initio method is used, when there is no template available. So, local fold of a sequence is 
predicted by computational method and then compared with other protein sequences. In the end, 
the whole protein is modelled. This method is suitable for smaller proteins with  less than 85 
amino acids (Bradley, Misura, & Baker, 2005). 
1.8.2.1 Homology modelling 
The basis of homology modelling relies on two observations: 
1) The 3D structure of a protein is determined by its sequence (Epstein, 1964) 
2) The fact that during evolution structural changes evolve much slower than changes in 
sequence, such that not only similar sequences but also related sequences fold into similar 
structures (Chothia & Lesk, 1986; Sander & Schneider, 1991). 
For homology modelling, a 3D structure of a similar (homologues) protein is required, which can 
be used to build the model of target protein. The higher similarity between template and target, 
the better chance for a good model to be built. But this similarity limit can vary among protein 
types. For example, for soluble proteins 30% similarity is considered as the borderline, but more 
than 50% is believed to produce high accuracy model. But for membrane protein the similarity 
between template and target can be very low (even less than 20%), but their structural identity 
can be high in transmembrane regions and the active site. So, using a structure of low similarity, 
it is still possible to generate model having reliable transmembrane region and active site (Ravna 
& Sylte, 2012).  





Figure 1. 7: Schematic diagram of homology modelling protocol.  
1.8.2.1.1 Template identification and sequence alignment 
A template can be the structure of a protein, which sequence fall into the ‘safe’ zone compared to 
the target sequence in terms of similarity. In practice, one can take the sequence of the target and 
using it as query sequence, make search for similar protein structures in any BLAST (Basic 
Local Alignment Search Tool) server and obtain hits with corresponding alignments. Sometimes 
some regions are found which are not so similar, and in that case the two sequences are aligned 
with other homologue sequences to fix regions of low similarity. This method is termed multiple 
sequence alignment (Krieger et al., 2003). 
1.8.2.1.2 Backbone generation 
When the alignment is ready, it is possible to create the model. It is done by copying the 
coordinates of the template to the new structure, according to the alignment. For identical 
residues, the side chain of the residues can be included (more rigid side chain as rotamer are 
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conserved), but if the residues are different only the backbone coordinate (N, Cα, C and O) can 
be copied (Krieger et al., 2003).  
1.8.2.1.3 Loop modelling 
Homologous proteins contain gaps, when aligned due to insertion and deletion in either of the 
sequences, which is referred to as loops. These loops are important in both structural and 
functional aspects. But it is very difficult to predict the loop conformation. There are two main 
approaches for loop modelling: 
1) Knowledge-based: Searches the PDB database for loops with matching residues to the 
target.  
2) Energy-based: an ab-initio approach to predict the fold and then the energy function is 
used to judge the quality, which is then minimized to possible best conformation (Krieger 
et al., 2003)  
1.8.2.1.4 Side-chain modelling 
As mentioned before, side chain can be obtained from the template in case of identical residues 
or need to be generate by ab-initio modelling. Naturally, protein side chains exist in limited 
number of low conformations, called rotamer. During modelling this rotamer is selected based 
on the sequence and then the backbone coordinates and the quality is assessed.  
1.8.2.1.5 Model optimization 
To have a model of high accuracy, it is required to have a correct backbone, which is dependent 
on correct side chain rotamer and packing. The rotamer prediction in turn depends on correct 
backbone. So, several steps of rotamer prediction and energy minimization is done until the 
whole structure is optimized. The energy function is very important for this step (Krieger et al., 
2003).  
1.8.2.1.6 Model validation 
It is almost obvious that errors will be introduced in the model structure, therefore it is required 
to validate the model before using it for structural predictions. This can be done by uploading the 
model to the structure analysis and verification server (SAVES; 
http://nihserver.mbi.ucla.edu/SAVES/) to check the stereochemical quality of the model. 
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Another approach is to dock known binders and non-binders in the model and check how good 
the model is distinguishing between them, which is a test of the accuracy of the binding site 
region.  
1.9 Docking  
After the development of the first algorithm for molecular docking, it became a popular tool in 
predicting conformations of small molecule ligands with the binding site of the target, with a 
degree of accuracy. This process includes two steps: exploration of potential binding 
conformation of the ligand and predicting interaction energy associated with each conformation, 
termed as scoring (Ferreira, Dos Santos, Oliva, & Andricopulo, 2015).  
In the conformational search, the degrees of freedom of the ligand, which is defined by the 
torsional, translational and rotational parameters, are increasingly modified. To detect suitable 
binding modes, the conformational search are using both systematic and stochastic search 
algorithms   (Ferreira et al., 2015). 
In systematic search, the conformation changes gradually and the energy landscape is explored 
for each conformations. After numerous search the minimum energy solution is selected as the 
most likely binding mode (Sousa, Fernandes, & Ramos, 2006). The problem with this is that 
number of possible combinations grows exponentially with the increasing degrees of freedom of 
the ligand, which leads to combinatorial explosion. Docking tools have their own strategy to 
handle this problem (Ferreira et al., 2015).  
In a stochastic method, conformations of the ligands are generated randomly until a low energy 
conformer is obtained. In contrast to systematic search, which is prone to select local energy 
minimum, stochastic method has higher chance of finding a global energy minimum (Zsoldos, 
Reid, Simon, Bashir Sadjad, & Johnson, 2007).   
1.10 Scoring 
The scoring functions estimate the binding energy by taking into account the physical chemical 
phenomenon like intermolecular interactions, desolvation and entropic effects, which are 
involved in ligand-target binding. So, the greater the number of considered parameters is, the 
closer the scoring functions are towards accuracy and reality (Ferreira et al., 2015). But due to 
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the computational costs involved, the scoring functions have to maintain the balance between 
speed and accuracy. Scoring functions are categorized as follows: 
Force-field based approach which takes into account the bonded and non-bonded interactions 
like van der Waals, electrostatic interaction and hydrogen bonding between all atoms of the 
binding partners in the complex. Solvation and entropic effects are also considered but not 
explicitly (Ferreira et al., 2015).  
Emperical scoring functions are based on counting the number of various interactions like 
hydrogen bonding, ionic and apolar interactions. It also considers the desolvation and entropic 
effects. These functions were found to be effective for several protein ligand complexes (Lionta 
et al., 2014). 
Knowledge-based function use statistical observations of intermolecular contacts in receptor-
ligand, whose structural conformations are established (Lionta et al., 2014).  
Although scoring functions are widely used to calculate the binding energies, it is also accepted 
that they usually fail to rank compound in proper order, and it is still a challenge to choose the 
correct binding pose as the top ranked one (Ferreira et al., 2015).  
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1.11 Aim of the study 
From the above discussion it is seen that the apicoplast is a metabolic hub in Apicomplexa 
parasites, which is fueled by the APT. Due to the plastidic nature of APT, it is a potential drug 
target. Among the APTs. TgAPT was studied best and its potential as a drug target was tested by 
disrupting the APT gene, which lead to the quick death of the parasite. So, finding inhibitors 
against this protein will not only help to develop drugs against T. gondii, but also against P. 
falciparum as the APTs of these organisms have significant similarity.  
There is no crystal structure of TgAPT available. But two 3D structures of a TPT from Galderia 
sulphuraria that was co-crystallized with two substrates (phosphate and 3-PGA) were published 
by Lee et al. (2017). Based on these structures, two homology models of TgAPT were generated 
in previous work (Vold, 2018) and named TgAPT_5Y78 and TgAPT_5y79. The models were 
optimized and validated. In this study, these two models will be used to: 
1) Predict potential inhibitors of TgAPT for in-vitro testing, using a ligand-based and 
structure-based virtual screening approach. 
2) Elucidate the binding site differences between TgAPT and PfoTPT, which has similar 
substrate specificity. For this a homology model of PfoTPT will be generated and 
compared with the TgAPT models. 
3) Compare the binding site of TgAPT with the binding site of other pPT subtypes and 




Figure 2. 1: Schematic diagram of the workflow 
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2.1 Structure import into Maestro workspace 
As already mentioned, there are two homology models of TgAPT generated by using triose 
phosphate transporter structure of G. sulphuraria as template. To view the previously generated 
models of TgAPT, the Schrodinger Maestro program was used on a Computer based on the 
Linux operating system. Before importing the files, the working directory was set to a desired 
location and the project was saved by a specified name “TgAPT_project”. After that from the 
“Import Structure” option under the “File” menu two models of TgAPT named “TgAPT_5y78” 
and TgAPT_5y79” were imported into the workspace from the specified folder. Only one of the 
structures will be appear on the screen, other one remained in the entry list.  
2.2 Renumbering the Models  
The template sequence was shorter than the target sequence, and during model generation, 
proper alignments of amino acids 1-38 amino at the N-terminal with the template was not 
obtained and these amino acids were therefore not present in the 3D TgAPT models. As a result, 
the 39th amino acid of the original sequence was numbered as 1, which created some confusion 
to track the important amino acids described in the literature. The sequences of the homology 
models were therefore renumbered starting with amino acid 39. For doing this, the 3D models 
were imported into the Schrödinger workspace and then opened from the task menu “Multiple 
Sequence Viewer”. The model sequence was now displayed on the screen in addition to the 3D 
model, and the renumbering option in the Edit panel was used to renumber the 3D model starting 
from amino acid 39 of the TgAPT sequence.  
2.3 Binding site comparison of TgAPT with other pPT 
As TgAPT has a unique substrate specificity, it was quite interesting to know the difference of 
the binding pocket of this protein with other phosphate translocators. In this process, only 
TgAPT_5y79 was used and firstly, comparison was done with the pPT classes: TPT, PPT, GPT 
and XPT and then specific comparison was done with a translocator from another species of 
Apicomplexa phylum, which reside in the outer membrane of apicoplast of Plasmodium 
falciparum.   
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2.3.1 Comparison with subclasses 
Before doing the comparison, it was necessary to identify amino acids in the binding pocket of 
TgAPT. For this, the crystal structure of GsTPT2 5y79, which was co-crystallized with 3-PGA, 
was imported into maestro suite. Then the co-crystallized ligand 3-PGA was selected, and the 
selection was expanded to 5 Å outside the ligand. By this way the amino acids within this region 
was selected and labelled, which resembles the binding pocket of the crystallized protein. Then 
the amino acids in TgAPT protein at these locations were detected by pairwise alignment. By 
selecting and superimposing these amino acids on the crystal protein the binding pocket was 
confirmed on TgAPT protein. Finally, the amino acids in the members of different subclasses at 
those specific locations were detected from an in-house sequence alignment (Appendix 1)  
2.3.2 Comparison with PfoTPT 
To do this study, a model of PfoTPT was prepared and then the binding site of the protein was 
examined and compared with TgAPT. The methods are described below. 
2.3.2.1 Homology Modelling 
For this method, ‘Prime Structure Prediction Wizard’ in Maestro suite was used. The steps 
followed in this method was according to the Prime user manual (Prime, 2019). Firstly, structure 
prediction wizard was opened from the task menu. The sequence of PfoTPT, triose phosphate 
transporter [Plasmodium falciparum 3D7] (accession no. XP_001351641.1) was derived from 
the NCBI database. After that, the sequence of the template structure was inserted from the 
workspace, which was the crystal structure with PDB-code 5Y79. This protein has two identical 
chains, and chain B was used for this task. In the next step, for the sequence’s alignment Prime 
STA (Single Template Alignment) method was chosen as the sequence identity was low (33%) 
between the template and target sequences. This alignment approach takes into account 
secondary structure matching along with sequence matching, which allows to generate better 
alignment in regions of low sequence conservation. By manual editing residue 1-35 of PfoTPT 
were cropped and some other changes were done to make the alignment look like the sequence 
alignment provided by Karsten Fischer (Appendix 1).  Then the structure was built. After 
finishing the model building, loop refinement was done according to default setting of the ‘Prime 
Loop Refinement’ tool as the loop length was less than six amino acid. In this setting the loop is 
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reconstructed using the backbone dihedral library, by building up half from each direction. By 
this way many loops were generated which then were clustered, and representatives of each 
cluster were selected. These loops are then ranked by assigning scores. Scores were assigned by 
the following procedures: side chains are re-added to the representatives. The loops and side 
chain were then energy minimized. Finally, the best scoring loop structures were returned. After 
that, the refined regions were energy minimized. Apart from this, steric clashes, bond length and 
bond angle deviations were updated through protein preparation tool. Finally, the energy minimized structures were 
exported as PDB files.   
2.3.2.2 Binding site detection 
The amino acids in the binding site of these two new models were examined as described in 
section 2.3.1. 
2.4 Searching for known substrates and inhibitors of TgAPT 
Before doing a virtual screening with a homology model it is important to know the reliability of 
the model is in terms of interactions with known substrates and inhibitors. Due to limited 
experimental binding data it was not possible to know exactly how the interaction would be, which 
means how the substrates fit into the binding pocket, which amino acids in the protein interact with 
the ligand and why non-binders do not bind and inhibitors inhibit the function of the protein. But 
still it is possible to make an assumption based on the experiments done in-vitro on this protein. 
From this idea literature search was done to learn about the active and inactive compounds which 
means compounds that are substrates, inhibitors, or not bind at all to the transporter. After 
generating a list, a prediction was made about the rank order of the different substrates based on 
their experimental affinity towards the transporter.  
2.5 Substrate and inhibitors docking in the homology models: 
One of the prescribed ways of testing a homology model is to dock known compounds of that 
protein into the model and check whether the result reconstruct experimental observations. That 
was done in the present study, and the procedure is explained below. 
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2.5.1 Ligand preparation 
2D structures of selected substrates and inhibitors were downloaded from the Pubchem database 
(https://pubchem.ncbi.nlm.nih.gov/) in “Sdf” format and included as entries into the Maestro 
workspace. After that, from the task menu of Maestro suit “Ligprep” program was opened. The 
structures of the substrates and inhibitors were used as input file by selecting these structures in 
the workspace and choosing Workspace in the “use structures from” option. For ionization Epik 
was chosen, which predict not only the ionization state but also the energetic state associated 
with them. The pH range for generation of states were 7.0  2.0. Keeping the ‘Desalt’ option, 
while generate tautomer option was deselected. For stereoisomer computation the specified 
chirality of the input ligands was kept. The output file was saved as “Ligands.3d.mae”.  
2.5.2 Protein preparation 
Before virtual screening it is required that a protein is prepared by fixing missing atoms and side 
chain, assigning bond order and formal charges, optimizing H-bond network and minimization of 
the structure. For this purpose, Protein Preparation Wizard in the Maestro Suit was used.  
The homology models of TgAPT were imported into the Maestro workspace and then the Protein 
Preparation wizard was turned on from the favorite toolbar of Maestro. In this program there are 
three tabs named ‘Import and Process’, ‘Review’ and ‘Refine’. By ‘Import and Process’ tab 
target protein is imported, if that is not already done and then basic structural fixation is done. 
There are several options under this tab, of them ‘Assign bond order’, ‘Add hydrogen’, Create 
zero-order bonds to metal’, ‘Create disulfide bond’ options were chosen. Also, water molecules 
beyond 5 Å of het groups were deleted and het states were generated within 7  2 pH. The 
function of ‘Review’ tab is to delete unwanted side chain and fix and delete het groups. Only for 
preparing the crystal structure this tab was used to delete one of the chains of the protein and 
remove the detergent molecules. Under the tab ‘Refinement’, optimization of H-bond network is 
done by reorientation of OH group, H2O molecules, amide group in Asparagine (Asn) and 
Glutamine (Gln), imidazole ring in Histidine (His), predicting the protonation stage of His, Asn, 
Gln as well as tautomeric states of His. After the optimization of H-bond, the structure was 
minimized by selecting all-atom minimization with a termination criterion based on the root-
mean-square deviation (RMSD) of 3 Å of the heavy atoms relative to their initial location. 
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2.5.3 Binding site prediction by Sitemap 
Information about the binding pocket is required for docking, but the pocket was not defined in 
the homology models of TgAPT, and it was necessary to predict the pocket. Prediction was done 
by the Sitemap program in Maestro. For the prediction, the default setting in Sitemap was used. 
In short, ‘Identify top-ranked potential receptor binding sites’ was selected, for hydrophobicity 
definition ‘More restrictive’ and for grid ‘Standard’ option was chosen. The site map was 
cropped at 4 Å from nearest site point. Using this setting 5 sites were reported. The most realistic 
was selected based on similarity with the binding site of the template structure (GsTPT2).  
2.5.4 Docking 
For docking the Glide docking tool was used. In this tool, the binding site of the protein has to be 
prepared as grid before docking. In this study the binding site was selected from the prediction 
by ‘Sitemap’. During receptor grid generation the van der Waals scaling factor was set to 1.0 and 
partial charge cutoff value was 0.25. After grid generation the ligands (prepared by Ligprep) 
were allowed to dock. There are three modes of docking in Glide: high throughput virtual 
screening (HTVS), standard precision (SP) and extra precision (XP), which differ in sampling 
ligand degrees of freedom and the scoring function employed. HTVS and SP uses the same 
docking algorithm and scoring function, but HTVS consider lesser ligand degrees of freedom 
and reduces final torsional refinement and sampling (Repasky, Shelley, & Friesner, 2007). On 
the other hand, XP does more extensive sampling than SP and employs a harder scoring function 
with greater requirement for protein-ligand shape complementarity. In this study, SP docking 
was used.  
2.6 Induced fit docking in TgAPT_5y79 
As the protein was kept rigid in the initial docking, it is possible that true substrates and 
inhibitors would score better if the amino acids in the receptor were allowed some movements, 
which may give better protein conformations for the SBVS process. This possibility was tested 
through “Induced Fit Docking” in Schrodinger Maestro Program Suite which was opened from 
the Task menu. In the “Ligands to be Docked” option, two of the substrates and two of the 
inhibitors were tried. Of the two substrates, one was phosphorylated at C-3position, which is 3-
PGA and another one was phosphorylated at C-2 position which is PEP. Among the inhibitors 
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one was phosphate containing, which is pyridoxal phosphate (PLP) and another one was sulfate 
containing, which is trinitro benzene sulfonate (TNBS).  Before docking, they were prepared by 
“Ligprep”. To define the amino acids for the grid box center, several docking using 3-PGA as 
ligand and trying different combination of amino acids in each run. In the first combination, 6 
amino acids were chosen which were His 126, Lys 145, Ser 204, Arg 207, Tyr 287 and Arg 311 
residing in TM respectively. In the second combination again 6 amino acids were chosen 
replacing Ser 204 with Asn 307. And finally, only 4 amino acids were selected which are His 
126, Lys 145, tyr 287 and Arg 311. Based on the best result, other three run were done with the 
remaining three ligands for induced fit. 
2.7 Virtual screening  
2.7.1 Pose selection for virtual screening 
After generation of several protein conformations (poses) by induced fit docking, the next 
challenge was selecting suitable poses for virtual screening. For this each pose was inspected 
visually. In this inspection several things were considered. For example, docking score, ligand 
position relative to the target, and especially the position of the phosphate group, and that the 
amino acids were interacting with the phosphate. In addition, similarity with the ligand 
interactions observed in the template crystal structures were considered. When an interesting 
pose was found, the whole binding pocket was superimposed with the binding pocket of original 
homology model as well as the crystal structure to see the structural change of amino acids 
during induced fit.  After selection of eight poses, the initial set of substrates and inhibitors were 
docked in those poses. Finally, the one, which produced comparatively better score than the 
initial docking and maintained the affinity order of the substrate most similar to their 
experimental affinity values, was chosen for the actual virtual screening.  
2.7.2 Analog Search 
Structural analogs of the inhibitors were downloaded from the Pubchem database. Firstly 
https://Pubchem.ncbi.nlm.nih.gov/# was accessed. In this page, several options were available on 
the right side and from there “Structure search” was selected. A new page appeared, from where 
identity/similarity was chosen. Under this option, there were three ways to define the target 
compound, for this study SMILES codes were used. Then, there were options to choose expected 
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similarity of the compound.  Similarity is measured by using Tanimoto equation and PubChem 
dictionary-based binary fingerprint. This fingerprint consists of a series of chemical 
substructures, termed as ‘Keys’. Each key represents presence or absence of a particular 
substructure in a molecule. These substructure keys do not take into account the stereochemical 
and isotopic variations. This is how these binary keys provide a chemical structure with a 
fingerprint. The degree of similarity is then selected by threshold parameter. For compounds like 
Pyridoxal phosphate, DIDS, 2,4,6-trinitrobenzene sulfonate and 4-sulfobenzenediazonium 80% 
threshold of similarity and for phenylglyoxal 90% similarity was chosen. Using these parameters 
search was done, and after that the structures were downloaded in SDF format.  
2.7.3 Docking the analogs 
Like the previous steps, the analogs were prepared with “Ligprep” and then docked on the 
protein conformations derived from 2.7.1 following the same procedure as described in 2.4.5. 
After that, a threshold score was set for each analog group. This threshold score was set 
considering the following: highest and lowest scoring value, score of the parent compound and 
number of compounds above the threshold score. For example- in the 3-PGA analog group, the 
highest scoring compound scored at -11.66 Kcal/mol, lowest scoring compound score -0.25 
Kcal/mol and 3-PGA itself scored -9.90. It was found that if the threshold score for this analog 
group is set to -9.0 Kcal/mol, a reasonable number of compounds can be extracted for visual 
inspection. For other analog groups threshold score was set in a similar manner. Compounds 
scoring above that threshold were exported as separate entries. There were some repeats of the 
same structure which were discarded. These isolated compounds were then examined and sorted 
by structural clustering.  
Table 2. 1: Threshold scores for selection of compounds for clustering. 
Parent compound 










According to Similar Property Principle by Johnson and Maggiora (1990) molecules having 
similar structure are likely to possess similar properties. That is the reason for that clustering 
provides with the possibility to cover bigger spectrum of compounds by allowing to choose one 
or two compounds in a cluster, as a representative for the whole cluster. For the clustering, the 
“Canvas” program in the “Schrodinger Suite” was used. Firstly the “Canvas” program was 
opened from the terminal and then the isolated structures of one of the analogs were imported. 
Then their hashed binary fingerprints were created by ‘Binary Fingerprint’ option in the 
‘Application’ Menu. In this study among the various types of hashed fingerprints ‘Molprint2D’ 
type was generated. It was incorporated in the program. Next, using the ‘Hierarchical Clustering’ 
application the compounds were clustered based on the fingerprint that was generated using 
‘Tanimoto Similarity’ metric and in the ‘Cluster Linkage Method’ ‘Average’ was chosen. The 
dendogram of the cluster was opened and some adjustments were done, such as reducing or 
increasing the number of clusters to make it convenient for further analysis. Finally, the 
structures in the clusters were exported in a separate file. Similar things were done for rest of the 
analogs. 
2.9 Sorting out compound from clusters:  
The clusters created in the previous step were imported in ‘Maestro’. These structures were then 
examined visually to look at their size, docked position, interaction and the score. By this manner 








3.1 Homology Modelling of PfoTPT 
Sequence alignment showed 33% similarity between the template (GsTPT2) and the target 
(PfoTPT) (Appendix 2), which can be considered acceptable as these are membrane proteins. 
Based on this alignment one model was built (figure 3.1). Similar to the template this model has 
10 transmembrane helices and the loops were predicted by the program. After the model built some 
of the loop regions were refined and these regions are residues 102-106, 217-220, 248-252, 261-
264. 
 
Figure 3. 1: Backbone of homology model of PfoTPT a) Side view. b) Top view 
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To evaluate the model, the model was superimposed on the template and rmsd between template 
and target was found to be 7.43. The PDB format of the model was uploaded to SAVES server for 
further evaluation.  The results are given below: 





53.09% of the residues have 
averaged 3D-1D score >= 0.2 
Fail 
Errat Overall quality factor: 93.64 
Prove 
Buried outlier protein atoms total 
from 1 Model: 4.6% 
Warning 
Procheck 
Out of 8 evaluations 
• Errors: 2 
• Warning: 4 
• Pass: 2 
 
The verify tool determine how compatible the 3D model is with its own sequence by predicting a 
structural class based on its location and environment (alpha, beta, loop, polar, nonpolar etc) and 
comparing it to high quality experimental 3D structures (Mannhold, Kubinyi, & Timmerman, 
2008). Compared to the expectation, which 80% of the residues scoring =>0.2 in 3d/1D 
profiling, this model scored 53.09%. 
According to ERRAT the overall quality factor is 93.64, which is an indication of structure 
reliability (Colovos & Yeates, 1993). 
The Prove tool calculates the z-score deviation of the model from the highly resolve PDB-
structures based on the volume of the atoms, where atoms are treated as hard spheres (Pontius, 
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Richelle, & Wodak, 1996). A model pass this when its score is <1 %, here the model scored 4.6 
% which is a warning. Scores > 5% is considered as failing. 
PROCHECK verifies the stereochemical quality of a protein (Laskowski, Macarthur, Moss, & 
Thornton, 1993) and this model passed in two, got warning in 3 and failed 2, out of 8 evolutions. 
As for the Ramachandran plot, which was also passed, showed 94.4% of the residues were in 
most favored regions, 4.9% in additional allowed regions and 0.7% were in disallowed regions 
(fig 3.2). 
   
Figure 3. 2: Ramachandran plot of PfoTPT model 
 3.2 Comparison of binding site 
The binding site comparison is presented in three parts:1) Between different classes (TPT, PPT, 
GPT and XPT), 2) Between TgAPT and PfoTPT and 3) Between two APT and all other classes. 
A number of sequences from higher plants in each subclass was included in this study. For 
example: 26 sequences of the TPT class, 30 of the PPT class, 19 of the GPT and 3 of the XPT 
class. 
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Twenty-three amino acids were found within 5 Å of co-crystallized ligand 3-PGA in the template 
structure 5y79, (Table 3.2) and these amino acids are distributed within in 7 helices (1,2,3,4,6,8,9 
helices). Similarity and differences in these positions between different classes and TgAPT and 
PfoTPT were determined as described in the method.  For the ease of presentation, the comparison 
is done by classifying these amino acids into three groups: Phosphate recognizing, Carbon body 
of the ligand recognizing and amino acids with no binding role. Another thing to note here is that 
the amino acid position of GsTPT2 will be considered as anchor and others will be compared 
relative to them.  
Table 3. 2: Amino acids within 5Å of co-crystallized ligand 3-PGA in GsTPT2 and corresponding amino acids 
in TgAPT, PfoTPT, TPT, PPT, GPT and XPT respectively. Yellow labels indicate differences from the 
corresponding GsTPT2 residues and the grey one in PfoTPT is the only difference between TgAPT and PfoTPT. In 
some cases, there were differences among the compared sequences of the same class, which is showed by 
mentioning the number of species (sp.) the difference is present 
GsTPT2 TgAPT PfoTPT TPT PPT GPT XPT 
Trp 116 Trp Trp Trp Trp Trp Trp 
Asn 120 Asn Asn Asn Asn Asn Asn 
Phe 123 Tyr Tyr PHe 
Phe/ tyr (3 
sp.) 
PHe PHe 
Asn 124 Asn Asn Asn 
Asn/ His 
(only 1 pr.) 
Asn Asn 
Asn 127 Asn Asn Asn Asn Asn Asn 
Gln 144 Gln Gln His Gln Ser Gln 
Gly 184 Val Val Gly Gly Gly Gly 
His 185 His His His 
Asn/ Thr 
(only 1 sp.) 
His His 
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Thr 188 Ala Ala 
Ser/ Thr (3 
sp.) 
Thr Ala Ala 
Cys 189 Val Val 
Asn ∕ Thr (3 
sp.) 
Asn Thr Cys 
Phe 192 Met Met Phe 
Leu (Ile 1 
sp.) 
Met Phe 
His 201 His His His His His His 
Lys 204 Lys Lys Lys Lys Lys Lys 
Glu 207 Glu Glu Glu Glu Glu Glu 
Ser 259 Ser Ser 
Ser / Ala 
(only 2sp.) 
Ser /Cys/ 
Ala (1& 1 
sp.) 
Ser ser 
Phe 263 Ser Ser Phe 
Asn/ Phe 
(Phe 8 sp.) 
Phe Phe 
Arg 266 Arg Arg Arg Arg Arg Arg 
Tyr 336 Tyr Tyr 
Tyr /Phe (1 
sp.) 
Phe / Leu (1 
sp.) 
Tyr Tyr 
Tyr 339 Tyr Asn 
Tyr /Asp (1 
sp.) 
Tyr Tyr Tyr 
Asn 340 Asn Asn Asn Gln Asn Asn 
Asn 359 Asn Asn 
Asn / Ser (1 
sp.) 
Asn Asn Asn 
Lys 362 Lys Lys Lys Lys Lys Lys 
Arg 363 Arg Arg Arg Arg Arg Arg 
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Phosphate recognizing residues, which are Lys 204, Lys 362 and Arg 363 in GsTPT2 are found to 
be conserved in all sequences examined here, most probably because of all proteins of the family 
have phosphates common as their substrates. For the amino acids involved in other part of substrate 
recognition or the amino acids close to them some differences were observed, which might 
contribute to the different substrate recognition by different classes. For example:  in place of His 
185, PPT contain Asn/ Thr, For Thr 188, TPT has Ser or Thr, GPT and XPT has Ala. And instead 
of Phe 263 in GsTPT2, the PPTs has Asn in some Phe in some. 
There are also differences between classes in the amino acids not directly involved in ligand 
interaction. For example: proteins of TPT class contain His instead of Gln 144, Ser/ Thr for Thr 
188, Asn/ Thr for cys 189 compared to the GsTPT2 protein. Similarly, PPT proteins has Phe/Tyr 
in place of Phe 123, Asn in place of Cys 189, Leu instead of Phe 192, Phe in place of Tyr 336 and 
Gln in place of Asn 340. In case of GPT, it has Ser in place of Gln 144, Thr for Cys 189. Among 
all classes XPT has the most similar binding pocket structure to GsTPT2 and differs only in one 
position, which is Ala for Thr 188. This difference may allow XPT to accommodate xylulose. 
As TgAPT and PfoTPT reside in the apicoplast and have the same substrate specificity (Brooks 
et al., 2010; L. Lim et al., 2010), it was expected that they have a very similar binding pocket. It 
was found that only one amino acid is different and that is an Asn in PfoTPT where TgAPT has a 
Tyr, while other amino acids in the binding pocket are similar in these two proteins. When these 
two proteins were compared with others it was found that the phosphate recognizing residues are 
similar, but there are differences in some positions. For example- for Phe 123. Gly 184, Thr 188, 
Cys 189, Phe 192 and Phe 263 in GsTPT2, TgAPT and PfoTPT both have Tyr, Val, Ala, Val, 
Met and Ser, respectively. Except for Thr 188 to Ala, the other differences with GsTPT2 are 
unique for these two proteins. 






Figure 3. 3: Differences of residues in the binding site of a) GsTPT2 b) TgAPT_5y79   c) PfoTPT 
3.3 Known substrates and inhibitors of TgAPT 
Previous work regarding this protein and other members of this protein family detected several 
known substrates and inhibitors, which were sorted into three categories: 1) Substrate, 2) Known 
non-transported compound and 3) Inhibitors (Table 3.3). Substrates are those compounds, which 
are transported through this protein. Known non-transported are usually not transported, but in 
experimental condition they might be transported. For example- glucose-1-phosphate (Glc-1-P) 
and fructose-6-phosphate (Frc-6-P) are not transported either in vitro or in vivo, but glucose-6-
phosphate (Glc-6-P) can be transported in vitro, but not in vivo (Brooks et al., 2010). The reason 
for that Pyrophosphate is considered in this group is that Lee et al. reported that the binding 
pocket of GsTPT2 cannot accommodate two phosphate group at the same time (Lee et al., 2017). 
From this, it was assumed that pyrophosphate was not supposed to be accommodated in TgAPT 
binding pocket either. The third category are inhibitors, which inhibit the transport process. 
Experiments of substrates and the non-transported compounds have been done on this protein 
(Brooks et al., 2010), and Ki
 
values of substrates based on inhibition assay of phosphate transport 
are given in table 3.3. From this, the compounds can be ranked according to TgATP binding 
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affinities, which is 3-Phosphoglyceric acid (3-PGA) > Triose phosphate > phohosphoenol 
pyruvate (PEP). For PfoTPT, the rank order is different, cause it has higher affinity for PEP as 
reflected on Ki value for competitive inhibition of [ 32 P]-Pi is 0.22 ± 0.03 mM, whereas for 
DHAP and 3-PGA that value is 1.53 ± 0.03 mM and 3.72 ± 0.40 mM, respectively (L. Lim et al., 
2010). This can be an indication for how the rank order of scoring should ideally be when these 
molecules are docked. For inhibitors no published affinity data was found for TgAPT and 
PfoTPT, but some amino acid reagents like pyridoxalphosphate, 2,4,6-trinitrobenzene-sulfonate, 
which reacts with lysine residue, phenylglyoxal which reacts with Arginine residue and 4-
sulfobenzenediazonium, which reacts with histidine and tyrosine were found to inhibit the 
phosphate translocation process of chloroplast phosphate translocator (Kenny, 1981). Therefore, 
these reagents are also considered as inhibitors of this TgAPT also. Beside this, 4,4’- 
diisothyanocyanostilbene-2, 2’-disulfonic acid (DIDS) is an inhibitor of this process (Gross, 















Table 3. 3:Known substrates and inhibitors of TgAPT with the structures and docking score in the two 
homology models and the crystal structure. TP= triose phosphate, 3-PGA= 3-phosphoglyceric acid, PEP= 
phosphoenol pyruvate, DHAP= dihydroxy acetone phosphate, Glc-6-p = glucose-6-phosphate, Frc-6-p= fructose-6-
phosphate, PP= pyrophosphate, PLP= pyridoxal 5’ phosphate, DIDS= Diisothiocyanostilbene-2, 2’ disulfonate, 4-
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3.4 Docking of substrates and inhibitors 
In order to assess the model quality and have an idea about the protein ligand interaction docking 
of the compounds in table 3.3 was done in the models. Among the homology models, the scoring 
and ranking of the compounds varied greatly. C-3 substrates comparatively scored better than the 
C-6 compounds and the inhibitors in TgAPT models. On the other hand, C-6 compounds scored 
better in PfoTPT models. 
 All the compounds except DIDS were docked in all models. One possible reason for that DIDS 
did not dock, may be the size (table 3.3).  Among the TgAPT homology models, the compounds 
scored best in TgAPT_5y79 model. In both TgAPT models the highest and lowest scoring 
compounds were the same, which were PP and 4-SBD respectively. But, the expected rank order 
of scoring of the substrates was not found in any of the models. According to scoring values for 
5y78 model c-3 compounds were ranked as DHAP (2nd), Gly-3-P (3rd), 3-PGA (5th), PEP (10th)  
and for 5y79 it is 3-PGA (3rd),  PEP (4th), Gly-3-P (6th), DHAP (10th),  none of which match with 
the expected 3-PGA > Triose-P > PEP.  The C-6 compounds appeared as Frc-6-P (4th), Glc-6-P 
(7th), Glc-1-P (8th) for TgAPT_5y78 model and Glc-6-P (2nd), Frc-6-P (9th), and Glc-1-P (12th) 
for TgAPT_5y79 model. For the inhibitors, the order was: Phenylglyoxal (6th), TNBS (9th), 
Pyridoxal-5-P (11th), 4-SBD (12th) for the TgAPT_5y78 model and Pyridoxal Phosphate (5th), 
Phenylglyoxal (7th), TNBS (11th) and 4-SBD (13th) for the 5y79 model. In comparison to TgAPT 
models, the PfoTPT model had quite different results. The order of the C-3 compounds were 
Gly-3-P (5th), 3-PGA (7th), DHAP (9th), PEP (10th), and for C-6 compounds Glc-6-P (2nd), Frc-6-
P (3rd), Glc-1-P (8th), while  for inhibitors the order was Pyridoxal phosphate (1st), Phenylglyoxal 
(6th), TNBS (11th), 4-SBD (12th).   
Next, the docking position of 3-PGA in these models were compared with the crystal structure 
template. It was found that, in none of the model, 3-PGA was docked in a position that was 
completely matching with the bound 3-PGA in crystal structure 5y79 (figure 3.3). From overall 
assessments, it was seen that TgAPT_5y79 scored better and showed better result in terms of 
differentiating between substrates and non- substrates than the TgAPT_5y78, although there was 
some ambiguity. But, the docking position of 3-PGA did not completely match with the crystal 
structure, which created some confusion. So, induced fit docking was done to identify better 
conformations of TgAPT for the interactions with the tested compounds. 
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Figure 3. 4: Position of 3-PGA in a) TgAPT_5y78 b) TgAPT_5y79 c) PfoTPT model d) Crystal structure 5y79. 
In homology models it is docked position and in the crystal structure it is the crystallized bound position. 
3.5 Induced fit in TgAPT_5y79 
As mentioned in the method section, three combination of amino acids were tested for grid 
generation. It was found that grid generated with the four amino acids (His 126, Lys 145, 
Tyr287, Arg 311) produced better result in terms of scoring and docking position (result not 
shown here). Using this combination, induced fit was done on TgAPT with 3-PGA, PEP, PLP 
and TNBS. From these four runs, 6 poses from 3-PGA, PEP and TNBS were selected initially 
based on scoring value and docked pose. Their pose and interactions with neighboring amino 
acids are shown in fig 3.4, 3.5 and 3.6. From PLP docking, better poses were not obtained after 
induced fit docking. 
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Figure 3. 5: Two poses selected from induced-fit docking with 3-PGA.  a) 3-PGA_A:2, Lys 145, Arg 311, Lys 
310 and Tyr 287 interacted with the Phosphate group, Tyr 284 form H-bond with OH of C-2 and Arg 207 interacted 





Figure 3. 6: Two potential poses from induced fit docking with PEP. a) PEP_A_3, Phosphate group has 
interaction with Asn 63 and Asn 59 along with Lys 145, Lys 310 and Arg 311, one of the Carboxyl O interact with 
Arg 207 and Tyr 287 and another O form salt bridge with Lys 145 b) PEP_A_11, it has also similar interaction 





Figure 3. 7: Poses from induced fit docking with TNBS a) TNBS_1, Lys 145, Lys 310 and Arg 311 interacted 
with Sulphate group.  Tyr 284, Arg 207, Arg 311 and Lys 145 interacted with the nitro group and Tyr 287 also 
showed pi-pi stacking interaction with the Benzene ring. b) TNBS_8, Lys 145, Arg 311 and Asn 307 interacted with 
both sulphate group and one of the nitro group as well. Arg 207 interacted with nitro group and Tyr 287 form similar 
Pi-Pi stacking same as previous one.  
b) 
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The poses selected after induced fit were mainly based on protein-ligand interactions. In the 
selected, the phosphate group of 3-PGA and PEP and the sulfate group of TNBS were 
recognized almost in a similar manner by Lys 145, Lys 310 and Arg 311 and the other part of the 
substrates were extended to the opposite side (fig 3.4, 3.5 and 3.6). Like the phosphate 
recognizing residues there was another residue which was found to be interacting with all the 
compounds, which was Arg 207. Beside this, Tyr 287 and Tyr 284 were also seen to be common 
substrate binding residues.  
Other interesting points to be observed were movements of side chains of amino acids in these 
selected poses compared to the initial positions in the model. In 3-PGA_A_2 conformation some 
movements of the side chain of Arg 207, Tyr 284, Asn 288, Tyr 287, Asn 307, His 122, Tyr 62 
were seen. In 3-PGA_B_2 Tyr 62, His 122, Lys 145, Arg 207 and Tyr 287 side chains changed 
their position. In PEP_A_3 Arg 207 and Asn 288 and in PEP_A_11 Tyr 62, His 142, Lys 145, 
Arg 207, Tyr 284 and Asn 307 side chain movement was visible. In TNBS_1 His 122, Arg 207 
and Tyr 287 and TNBS_8 His 122, Lys 145, Arg 207 and Asn 307 moved their side chains a bit. 
3.6 Selection of docking pose for virtual screening 
As mentioned in the method section, the substrates and inhibitors were re-docked in the selected 
poses after induced fit. The results are presented in table 3.4. After re-docking, one of the models 
with 3-PGA, 3-PGA_A_2, scored highest and had a better rank order of the compounds than the 
others. Although the rank order of the compounds is slightly deviating from the rank order from 
experimental studies (PEP ranked 2nd and Gly-3-P was 3rd), it was still the best ranking among 
the obtained model conformations. Interestingly DIDS also could dock in this model. Both 
models with PEP have some positives and negatives. PEP_A_3 model scored good, but in 
ranking frc-6-P came before Gly-3-P, which is a drawback of this model. Then, PEP_A_11 
scored less than the two models with 3-PGA and PEP_A_3 and Glc-6-P and Frc-6-P scored 
better than PEP in this model. Of the six models tested here, these three models had good scoring 
value and closer to actual rank order of the compounds. Other models selected from induced fit 
(3-PGA_B_2, TNBS_1 and TNBS_8) had more deviant ranking of the compounds, although 3-
PGA_B_2 scored good.  In overall comparison, 3-PGA_A_2 showed the best results and that 
model conformation (docking pose) was therefore selected for virtual screening. 
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3.7 Virtual screening 
In this study, ligand-based screening was done by searching the analogs of the substrates and 
inhibitors in the PubChem database and structure-based screening was done by docking the 
analogs in the TgAPT_5y79 model. Interestingly, the ligand-based step showed that inhibitors 
that contain ring structure had more analogs than the substrates with linear structure. 
Table 3. 5: Analog search, docking and filtering of compounds. Similarity threshold is the parameter to dictate 
structural similarity between analogs and the parent compound. To sort the compounds from large number of docked 
analogs, Threshold scoring value was used and filtered compounds are number of compounds scored above the 
threshold value. 




After Ligprep Threshold score Filtered               
compounds 
3-PGA 80% 469 2400 -9.0 90 
Gly-3-P 80% 166 578 -7.0 16 
PEP 80% 64 128 -7.0 15 
PLP 80% 2267 11293 -8.0 40 
DIDS 80% 1883 3626 -7.0 36 
TNBS 80% 1848 2312 -7.0 25 
4-SBD 80% 3267 4572 -7.5 40 
Phenylglyoxal 90% 1426 1965 -6.0 56 
 
Of all the compounds 4-SBD has the highest number of analogs within the search criteria. After 
Ligprep modification, PLP analogs gave the highest number of compounds. In the process of 
sorting out compounds for closer inspection, cut-off scoring values were used. Although scoring 
value is not an ideal parameter to justify affinity between protein and ligand, it is still a widely 
accepted tool to predict protein ligand interaction during virtual screening. As, it was not 
possible to inspect all the protein-ligand complex visually, therefore threshold scores were used 
here for initial screening. Different threshold scores for different set of analogs were used 
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because those sets scored differently during docking and the parent compounds also had different 
scores. In some cases, comparatively lower score was used to have considerable number of 
compounds in that set. So, in this manner highest threshold score was used for 3-PGA analogs, 
which is -9.0 kcal/mol and above that score there were 90 compounds, which is the largest 
amount among all analog sets. For Gly-3-P and PEP analogs the same cut off score was used (-
7.0 kcal/mol), and 16 and 15 compounds were filtered from each group respectively. For 
inhibitors, the highest number of compounds were analogs of both PLP and 4-SBD group (40 
from each) above -8.0 kcal/mol and -7.5 kcal/mol cut-off score respectively. For DIDS and 
TNBS -7.0 kcal/mol cut-off score was used, giving 36 and 25 analog compounds. Finally, for 
Phenylglyoxal lowest cut-off score was used (-6.0 kcal/mol) and from this group 56 were sorted 
out. 
3.8 Clustering 
Isolated compounds in the previous step were clustered based on 2D similarity. Usually, one 
compound in a cluster represents some common features of all the compounds in that cluster. By 
this manner choosing one compound from a cluster can give an idea about the activity of that 
cluster. Output of clustering is summarized in table 3.6.   
Table 3. 6: Clustering of sorted compounds from analogs docking 
Analogs of Merging distance No. of clusters Largest cluster 
3-PGA 0.79 11 
Cluster no: 3 
Compounds: 44 
Gly-3-P 0.82 3 
Cluster no: 1 
Compounds: 11 
PEP 0.81 5 
Cluster no: 1 and 2 
Compounds: 5 
PLP 0.80 7 
Cluster no: 6 
Compounds: 23 
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DIDS 0.68 5 
Cluster no: 4 
Compounds: 18 
TNBS 0.75 7 
Cluster no: 4 
Compounds: 12 
4-SBD 0.79 8 
Cluster no: 4 
Compounds: 27 
Phenylglyoxal 0.81 9 
Cluster no: 3 
Compounds: 18 
 
During clustering, the cluster number varies with the merging distance. It is a parameter to 
justify how similar the compounds are. If two compounds form a cluster with a short merging 
distance, that means those two compounds are highly similar. So, increasing the merging 
distance will reduce the number of clusters. In this study, relatively longer merging distances 
were used, so, a smaller number of clusters were generated. Longest merging distance was used 
for the Gly-3-P analog group and smallest for the DIDS group which were 0.82 and 0.68 
respectively. In that way these two-group generated 3 and 5 clusters, respectively. After Gly-3-P, 
both PEP and Phenylglyoxal group with the same merging distance 0.81 generated 5 and 9 
clusters respectively. 3-PGA and 4-SBD both groups also had the same merging distance of 0.79 
and generated 11 and 8 clusters in respective manner. Then PLP group produced 7 clusters with 
a merging distance of 0.80 and TNBS group produced 7 clusters with 0.75 merging distance. 
Interestingly, almost all groups, except TNBS had 1 cluster with the majority of compounds. For 
example, in 3-PGA, PLP and 4-SBD groups all had 1 cluster containing 44, 23 and 27 
compounds out of 90, 40 and 40 compounds in those particular group. In Gly-3-P group 11 
compounds were in the same cluster out of 16 compounds. Phenylglyoxal and DIDS group also 
had large clusters with 18 and 18 compounds out of 56 and 36 compounds in respective group. 
3.9 Predicting compounds for in vitro testing 
As mentioned in the method only the best scoring compounds with good interactions were 
suggested for in vitro testing. To be more specific, compounds within the first 10 in terms of 
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docking score in each group were chosen. For the ease of presentation, the compounds will be 
addressed according to their ranking within the particular group. 
Total 29 compounds are selected of which 6 were from PLP group, 5 from 4-SBD group, 4 from 
each of DIDS, 3-PGA and PEP group, 3 from TNBS and Phenylglyoxal group.  These 
compounds were selected from 5 clusters of the PLP group, 4 from each of DIDS, 4-SBD and 
PEP, 3 from TNBS and 2 from phenylglyoxal group. 
Among the 3- PGA anlogs 1st and 2nd best scoring compounds were from cluster 4, 3rd best from 
cluster 5 and 7th from cluster 3 were selected. In these selected clusters 4, 5 and 3 there were 18, 
18, 2 and 44 compounds respectively. Of the PEP analogs 1st, 2nd, 5th and 6th compound was 
chosen from cluster no. 3, 5, 2 and 4 and in these respective clusters number of compounds were 
1, 2, 5 and 2. 
Among the predicted inhibitors, PLP analogs were the highest scoring compounds. Of them, the 
1st was from cluster 7 and the 2nd from the same cluster. Other than these two, 3rd, 5th, 6th and 10th 
from cluster 1, 4, 6 and 3 were also chosen and these clusters contained 1, 5, 23 and 2 
compounds respectively. The analogs of DIDS did not scored as good as those of PLP, but still 
considerable for in vitro testing and from this group 1st, 2nd, 4th and 6th from cluster 1, 2, 4 and 3 
were suggested. In these clusters the number of compounds was 6, 6, 18 and 4 respectively. 
Among the 5 compounds from 4-SBD group, 1st and 2nd best scoring compounds were from 4th 
cluster where 27 compounds gathered. Other than these, 4th, 5th and 9th were selected which were 
stacked in cluster no. 1, 8 and 6 along with 2, 3 and 3 compounds. From TNBS analogs 1st, 2nd 
and 3rd best scoring molecule from cluster no. 4, 3 and 7 were chosen and in these clusters, there 
were 12, 6 and 2 molecules respectively. Phenylglyoxal group had the lowest scoring analogs, 
but, still 3 compounds were selected. Of them 1st and 2nd were from cluster 3, which contain 18 
compounds and the 3rd one is from 5th cluster which contain 6 compounds.  List of the selected 





Table 3. 7: List of predicted compounds 
Analog of 






Total compounds in the 
cluster 
3-PGA 
1st -11.66 4 
18 
2nd -10.52 4 18 
3rd -10.5 5 
2 
7th -10.36 3 
44 
PEP 
1st -10.80 3 1 
2nd -10.11 5 
2 
5th -9.58 2 
5 




1st -10.26 7 
7 
2nd -9.71 7 7 
3rd -9.15 1 
1 
5th -8.84 4 
5 
6th -8.77 6 23 
10th - 8.65 3 
2 
DIDS 
1st -7.95 1 
6 
2nd -7.93 2 6 
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4th -7.78 4 
18 




1st -8.86 4 27 
2nd -8.53 4 
27 
4th -8.39 1 
2 
5th -8.29 8 3 




1st -8.43 4 12 
2nd -7.80 3 
6 
3rd -7.75 7 
2 
Phenylglyoxal 
1st -7.93 3 18 
2nd -7.54 3 
18 







The purpose of this study was to predict potential inhibitors of TgAPT. There were two 
homology models of this protein available from a previous study and for better understanding of 
the binding site, a comparison was done with different subclasses of Phosphate translocator and a 
similar protein from Plasmodium falciparum apicoplast. In this process a homology model of 
PfoTPT was generated. Known substrates and inhibitors were docked in the TgAPT models and 
PfoTPT model. A reliable conformation (docking pose) of TgAPT was generated by induced fit 
docking and then analogs of the substrates and inhibitors were docked in that conformation. 
From this docking, compounds were predicted as inhibitors based on the scoring value and 
interaction modes.  
4.1 Homology Modelling 
Template for the model generation of the PfoTPT model was the same as the template for the 
TgAPT model (PDB id: 5y79). Sequence alignment showed it has 33% similarity with the 
template, which is less than for the TgAPT sequence. But it is above 30% similarity, which is the 
minimum requirement for a generated homology model to be comparable with an X-Ray 
structure of low resolution (Xiang, 2006). Actually as this APT is a membrane protein, it has 
little bit wider similarity window for generating a considerable good model (Ravna & Sylte, 
2012). When the PfoTPT model was evaluated with different tools, it was evaluated to pass in 
some, got warning in some and failed in some.  
Of the verification tools Verify3D  assessed the compatibility of a 3D model with its own amino 
acid sequence (1D) using a 3D profile, computed from the atomic coordinates and then score is 
given for each amino acid based on a probability of observing that particular amino acid in the 
environment observed in the protein structure. The PfoTPT model failed this test as the model 
had only 53.09% residues averaged 3D → 1D score => 0.2, whether in case of a good model at 
least 80% residues do that. In the window plot, in some regions, residues are found to score 
below zero, which are residue 121 to 141 and 211 to 231. This indicates that the conformation is 
not correct in these region (Mannhold et al., 2008). Actually, both of these are in loop region, 
which is the most notorious region of a protein. And most of the part of helix 2 and helix 3 
scored below 0.2, which indicates their lower conformation than the standard. It might because 
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of the difference between template and target, which can lead to alignment error which leads to 
problem in identifying structurally equivalent residues despite their presence (Petrey & Honig, 
2005). The Verify3D tool and other verification tools have been developed for checking the 
quality of 3D structures of soluble proteins and not membrane proteins. Most membrane proteins 
have in general more amino acids in helixes than soluble proteins and some evaluation tools may 
be a bit misleading for membrane proteins. 
ERRAT calculates the statistical organizations of particular type of atom relative to each other 
and hence gives a ‘Overall Quality Factor’ for non-bonded interactions (Colovos & Yeates, 
1993). By scoring 93.64 in this, the PfoTPT model passed the validation.  
Another evaluation tool PROVE, which calculates z-score deviation for the protein by 
calculating the volume of the atom considering them as hard spheres (Pontius et al., 1996). The 
model here got warning in this tool as it has 60 outlier buried atoms (4.6%), which means these 
atoms have volume more than 3.0 standard deviation away from the mean of their particular 
type.  
The PROCHECK gives an idea about the stereo-chemical characteristic of the protein model 
based on Ramachandran plot (Laskowski et al., 1993). The Ramachandran Plot showed that 
PfoTPT model has 94.4% and 4.9% in the favored and additional allowed region, which is an 
indication of a good model because a good model is supposed to have more than 90% of residues 
in allowed and favored region (Laskowski et al., 1993). 
From overall assessment, it can be said that the quality of the PfoTPT model is satisfactory and 
can be used for docking and predicting protein-ligand interactions. 
4.2 Comparison of binding sites among Phosphate translocators 
From the alignment (Appendix 1) it is seen that the proteins in this class are mostly conserved in 
their binding pocket, but there are differences, which may explain differences subtype substrate 
specificity. A common feature of the substrates of these proteins is the phosphate, so, there 
should be commonality in the recognizing of phosphate group(s) between the transporters. In this 
study total 78 sequences of different subtypes from higher plants were compared and all of them 
contained the same amino acids that recognizes phosphate. Actually, not only the core phosphate 
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binding, also the vicinities of these residues are conserved, which is consistent with a previous 
study (Lee et al., 2017). On the other hand, residues near the sugar moiety showed major 
differences. These differences along with their possible role in substrate recognition is discussed 
below in comparison with the GsTPT2 structure. 
Although GsTPT2 and TPT proteins transport similar substrates there are three residues different 
between these two proteins. Of them two differences are not common, but tolerable, which are 
Gln 144 and Cys 189 in GsTPT2, which corresponds to His and Asn/Thr respectively in TPT. 
Another is Thr 188 to Ser in TPT. Thr 188 was found to be involved in hydrophobic interaction 
with the substrate (Lee. 2017), but transformation of this into Ser in TPT did not affect the 
substrate specificity. The reason for that must be the similarity between Ser and Thr.    
The PPT binding site has 6 differences with the GsTPT2 binding site. Of them His 185 to Asn 
and Phe 263 to Asn in PPT are the two most important substitution compared to GsTPT2. His is 
chemically unique and involved in substrate binding. Replacing it with Asn surely affects the 
protein behavior. Similarly, Phe is a big aromatic amino acid, which may cause steric clashes 
with the branched side chain of PEP causing lower preference of PEP in other Phosphate 
translocators. So, replacing it with Asn in PPT allows the protein to accommodate PEP in the 
widened binding pocket. Other differences, Cys 189 to Asn, Phe 192 to Leu, Tyr 336 to Phe, Asn 
340 to Gln may also have some impact on PEP transport. 
GPT binds the largest substrates and should have a wider binding pocket than the others. From 
the binding site analysis, it was seen that two differences of GPT compared to GsTPT2 cause the 
widening. One is Ser in place of Gln 144 and another one is Ala in place of Thr 188. Ser and Ala 
both are smaller than Gln and Thr, respectively. Thr 188 was also seen to play a role in substrate 
recognition by hydrophobic interaction, so, transforming it into a very nonreactive Ala will also 
have some effect in GPT. Other than this, Cys 189 to Thr in GPT, which is a substitution into a 
similar amino acid, and Phe 192 to Met, which is a change of an aromatic hydrophobic to an 
aliphatic hydrophobic amino acid, may also contribute to differences in substrate specificity. 
For XPT, only one amino acid difference was found with GsTPT2 and that was Thr 188 to Ala and 
it seems that this change is enough to accommodate Xylulose in the XPT binding pocket. 
 57 
TgAPT and PfoAPT, both transport triose phosphates and PEP in natural conditions and also 
Glucose 6 Phosphate in experimental conditions although in low quantity (Brooks et al., 2010) 
From this, we can be assume that the binding pocket of these two proteins should have some 
commonality with TPT, PPT and GPT, especially the substrate recognizing residues. In this 
study, some of the characteristic residues are predicted above and in the following their 
commonality with two APTs will be mentioned. 
In TPT, His 185 was assumed to be one of the substrate binding residues and in both APTs this 
His is present. In both APTs, like PPT, Phe 263 (GsTPT2 numbering) is transformed into a polar 
amino acid, although it is Ser in APTs and Asn in PPT. It was seen that this amino acid is very 
crucial in PEP recognition (Lee et al., 2017). So, substitution of this amino acid in both PPT and 
APTs resemble their similarity. The APTs also show similarity with GPT in position 
corresponding to Thr 188 and Phe 192 of GsTPT2, where both the APTs and GPT contain Ala 
and Met respectively. However, there are some residues which are unique to the APTs. For 
example: Phe 123, Gly 184, Cys 189 in GsTPT2 to Tyr, Val and Val, respectively, in both APTs. 
The first two are comparatively similar type of amino acid, although Val is larger than Gly, but in 
place of Cys 189 the uniqueness to APTs is that other PPTs contain polar residue on this site, 
whether Val in non-polar. 
TgAPT and PfoTPT transport the same substrates, but with different affinity (Lim et al., 2010) 
and therefore should have some difference. Interestingly, only one amino acid was found to be 
different in these two proteins and that is in position of Tyr 339 in GsTPT2, where TgAPT 
contains Tyr like the others, but pfoTPT contains Asn. This Tyr 339 was seen to interact with the 
phosphate group by a hydrogen bond, so, substitution of with Asn in PfoTPT should be 
influential. Probably, it can give some idea about the differences in substrate affinity. 
Based on the alignment (Appendix 1), it was tried to give an overview of the similarity and 
differences in the binding pocket of different PTs and correlate the differences with their 
substrate specificity. But, the role of the amino acids was mostly assumption as the structural 
data was not available. So, to identify the specific role of important amino acids, site-directed 
mutagenesis and subsequent transportation experiment should be done. 
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4.3 Docking of known substrates and inhibitors in the homology models 
In order to get some idea about the behavior of homology models, known substrates and 
inhibitors were docked in the models. The output showed some unexpected result. According to 
Lee et al. 2017, the binding pocket of Phosphate translocator cannot accommodate two 
phosphate groups at the same time, but pyrophosphate not only docked, but also was among the 
high scoring compounds in all the models. To exclude the probability of having problem with the 
model, the same compounds were docked in the crystal structure 5y79, which was used as 
template for homology modelling, and a similar result was obtained found in case of 
pyrophosphate (Data not shown here). This result produced an ambiguity, but in vitro experiment 
may give a better insight of this problem. 
The next problem of the docking was the ranking of the compounds. Experimentally, it was seen 
that TgAPT and PfoTPT does not readily transport Glc-6-P and other hexose phosphates (Brooks 
et al., 2010; L. Lim et al., 2010). But in the docking, Frc-6-P and Glc-6-P scored better than the 
actual substrate 3-PGA and PEP in TgAPT_5y78 model and Glc-6-P scored better than all other 
substrates in TgAPT_5y79 model. In PfoTPT model, Glc-6-P and Frc-6-P came in the 1st and 2nd 
position. Actually predicting binding affinities and rank them in order is one of the biggest 
methodological challenges in docking (Leach, Shoichet, & Peishoff, 2006). The scoring 
functions also have a lot of limitations. Using additional scoring functions can give better result. 
One of the reasons for incorrect prediction can be the condensed phases of biology in which it 
occurs and the degree of freedom of biomolecules (van Gunsteren & Berendsen, 1990). Beside 
this, the accuracy of the homology model itself might be an issue. 
Another important purpose of docking was not fulfilled either, which is to predict the correct 
binding mode of the ligand. None of the models could perfectly generate a pose of 3-PGA 
similar to the crystallized pose in the template structure. The interaction found did not 
completely match with the crystal structure. The ionic interaction of His 126 with the carboxyl 
group of C-1 was not seen in any of the poses, although phosphate recognition was similar.  
During docking the receptor was considered rigid and the ligands were allowed flexibility, but in 
reality, during ligand recognition and binding the protein conformation is changed very often. 
This can be a factor for the ligand not to be docked in the expected position.  
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One point to be noted is the low scoring value of phosphate in all the models. There is a water 
molecule present in the binding pocket, which plays a crucial role during phosphate binding (Lee 
et al., 2017).  That water molecule was not considered in the docking and may be a probably for 
that phosphate has low score in all models.  
Overall, the docking gave an idea about the behavior of the models and TgAPT_5y79 showed 
better result than other models. So, this model was chosen for induced fit docking to find a better 
conformation for the actual screening.  
4.4 Induced fit docking and selection of pose for virtual screening 
The purpose of the induced fit docking was to find a conformation for virtual screening of 
unknown compounds by allowing some flexibility in the binding site of TgAPT_5y79 model. 
Although the goal was to find a pose that will mimic the interaction in the crystal structure, but 
none of the conformations could do that. So, from the binding modes which were close to those 
in the template, complexes were selected for further inspection. 
In the selected poses, phosphate binding Lys 310 and Arg 311 did not move in regard to their 
position in the initial model. Only Lys 145 of the three phosphate binding residues moved during 
induce fit. On the other hand, Arg 207, which has been found to interact with ligands via ionic 
interaction or salt bridges, moved the side chain in every pose. Other than this, His, Tyr and Asn 
of different positions changed their side chain positions in the different poses. Observing these 
movements, the next question was which model conformation should be picked for the virtual 
screening. 
To find the answer, initial substrates and inhibitors were docked again in each pose, and then 
based on their scoring values, interactions in the binding pocket and rank order of affinities, the 
3-PGA_A_2 model was selected. In this model all compounds were docked including DIDS, 
which did not dock in any other, so it resembles the ability of the model to dock larger 
compounds beside smaller compounds. After that only PEP_A_3 had close result to 3-PGA_A_2 
model, but ranking order was slightly distorted as PEP scored a bit lower and Frc-6-P scored 
higher and was ranked 4th. In other models, ligands had lower score and more deviant scoring 
rank order of the compounds than expected.  
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Although only based on this, it is not wise to exclude the possibility of other poses, but due to 
shortage of time and also for simplifying the study, only one model was chosen for the screening 
step.  
4.5 Virtual screening 
In this study structural analogs of both substrates and inhibitors of TgAPT protein were used in 
search for potential new inhibitors. The idea of using inhibitor analog came from the fact that 
structurally similar compounds most often possess similar functional activity. So, among the 
analogs of an inhibitor, it is possible that some compounds will have the same function as the 
parent compound with better affinity. On the other hand, from the analogs of substrates, 
molecules with better interaction and affinity with the protein can also be extracted, which will 
bind to the binding site, but not be transported.  
In this study, out of 26874 docked molecules, 318 were extracted from the different groups of 
analogs based on their scoring values. Of them, most were analogs of 3-PGA. A reason for these 
compounds had better scores than others, may be that this pose was selected from induced fit 
docking of 3-PGA. From the other two substrate analog groups few compounds were extracted 
although lower cut-off scores were used. Actually, these two substrates had a smaller number of 
analogs in the first place.  
For the inhibitors, the highest number of compounds were analogs of PLP and 4-SBD (40 from 
each group), using the cut-off score -8.0 Kcal/mol and -7.5 Kcal/mol for the respective groups. 
One interesting thing to notice was that, 4-SBD itself had low score, but its analogs scored better 
and even giving a threshold score higher than TNBS, DIDS, Phenylglyoxal, PEP and Gly-3-P, 
and a larger number of compounds were possible to extract. From the TNBS and DIDS groups 
also a considerable number of molecules were obtained. These two inhibitors had a quite similar 
number of analogs, but after Ligprep preparation the number of DIDS analogs increased since 
DIDS analogs have a higher number of enantiomers. So, although same threshold score was 
used, number of molecules in the DIDS group was higher.  
For the phenylglyoxal group the lowest cut-off score of all was used, and 56 compounds scored 
better than the threshold. Although a good number of analogs were found under 90% similarity, 
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but within this limit not that much modification can be expected compared with phenylglyoxal to 
increase the interaction capability.  
4.6 Clustering of selected analogs 
It is a common notion that similar structure tends to have similar properties. On the contrary, it is 
also true that slight change in the structure can lead to functional change of that compound 
(Zahoránszky et al., 2009). Despite this possibility, the extracted analogs were clustered based on 
their similarity. There are several fingerprint methods, which are used to cluster compounds. As 
for the compounds whose correct fingerprint type is uncertain, it is recommended to use 
MOLPRINT2D, which was used here (Duan et al., 2010; Sastry et al., 2010). Then the ligands 
were clustered by hierarchical clustering with relatively longer merging distance. In case of long 
merging distance there is a chance of less similar compounds getting into one cluster which can 
increase the chance of identifying more dissimilar to known compounds as inhibitors.   
The clustering result showed that majority of the compounds of an analog group gather into one 
cluster, which indicates that most of the compounds are close to each other. And rest of the 
compounds get separated into several clusters, which is a reflection of their relative dissimilarity. 
For example, for the PLP and 4-SBD analog groups that both contained 40 compounds, 23 and 
27 compounds from the respective groups gathered into one cluster, while the rest of the 
compounds dispersed into 6 and 7 clusters respectively. For DIDS analogs having lowest 
merging distance, out of 36 molecules 18 were gathered into one cluster and rest of the 
compounds diffused into 4 clusters indicating that there are significant differences among them. 
TNBS and Phenylgloxal analogs also have variation in their structure as seen in their cluster 
number. In case of 3-PGA, although it shows that there are 11 clusters, but 80 out of 90 
compounds gathered into 3 clusters, which justifies their structural similarity. PEP and Gly-3-P 
analogs also had more similar compounds than dissimilar ones.  
4.7 Selection of compounds 
The docking score and the mode of interactions with the binding site were the main criteria for 
selecting compounds for experimental testing.  Amino acids proved to be involved in phosphate 
recognition and binding are Lys 145, Lys 310, Arg 311, while His 126, Arg 207 and Tyr 287 
were found important for recognizing and binding with the rest of the ligand. Site directed 
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mutagenesis studies have confirmed their importance in the transport (Lee et al., 2017; Takemoto 
et al., 2018). Following this pattern of interaction and scoring values, 29 compounds were 
suggested for experimental testing.  
One common feature of the selected compounds are negative ions contributed by mostly Oxygen 
atoms, which lead to the ionic interaction with the positively charged amino acids, especially Lys 
145 and 310, Arg 207 and 311. That might be one reason for that more negative ions scored 
highest.  
Closer inspection also revealed that all the selected compounds were found to have common 
interaction with Lys 145, Lys 310, Arg 311, Arg 207 and Tyr 287. Beside this some of the 
analogs were found to have additional interaction, for example- 4-SBD, DIDS and TNBS 
analogs showed interaction with Asn 288. In addition to the good interactions, some bad 
interactions were found in some of the analogs of DIDS and TNBS having bad contact with His 
126 and Tyr 284. 
Some of the clusters containing low scoring compounds were not selected despite having the 
probability of a good candidate scoring low in docking experiment. Keeping all these drawbacks 
under consideration compounds were finally selected. The compounds will be experimentally 
tested for their inhibition potential.  
5 CONCLUSIONS  
The main purpose of this study was to predict potential inhibitors against TgAPT. Before going 
to the actual screening, the binding site of TgAPT was compared with PfoTPT and pPT classes. 
This comparison revealed that the binding pocket of these protein share mostly common 
residues. There are also differences as well, which might contribute to their substrate specificity. 
Interestingly, TgAPT and PfoTPT were found to be very similar in their binding site, differ in 
only one amine acid. These both proteins have similar substrate specificity, so it can be assumed 
that inhibitor of TgAPT possibly inhibit PfoTPT. 
Through LBVS and SBVS approaches, 29 compounds were finally predicted as potential 
inhibitor. These compounds showed good scoring with a 3D model of TgAPT, but it is not 
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possible to be sure that all of them are true TgAPT binders.   To explore the possibility of these 
predicted compounds they needed to be tested experimentally. 
7 FUTURE DIRECTION 
Experimental tests will be done in the laboratory of Prof. Eva Pebay-Peyroula (University of 
Grenoble, France) who is a collaborator in this project. Inhibition is shown by two different 
experimental strategies. First, the compounds are analyzed for inhibition in biochemical transport 
assays of the APT protein which is integrated into artificial liposomes. If these results are found 
to be positive, then their ability to inhibit growth or kill the parasite is directly determined in cell 
cultures of host and Toxoplasma cells. In the case of a positive outcome from this test these 
compounds will be also tested in cell cultures with Plasmodium as parasite. By this manner, a 
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Appendix 1:  Sequence comparison between the phosphate translocators 
 
                                  
 
 SoTPT  A-ASGS----- -S-GEAKT---- -GFLEKYPAL VTGSFFFMWY FLNVIFNILN KKIYNYFPYP--   50 
 McTPT  .A.E..----- D.A....V---- -...Q..... ...F...... .......... ..........--   53 
 VvTPT  .ST.SPAEGS- D.A.D..I---- -...D..... ...F...... .......... ..........--   57 
 VvTPT2 .A.AADADG-- --VV.PA----- KSLS.RF... ......MT.. .S.IV..... ..V.......--   54 
 VvTPT3 .A.AADADG-- --VTKPS----- KS.A..F.V. ...F...... .......... ..V.......--   54 
 PsTPT  .T.G.N----- D.A..E.VAP-- V..FSR.... T..F...T.. .......... ..........--   56 
 AtTPT  .-.--AAEGG- DTA.D..V---- -.......W. ...F...... .......... ..........--   54 
 BoTPT  .-..--AEGG- D.A..T.V---- -...G...W. ...F...... .......... ..........--   54 
 PtTPT1 .A..SPAEGS- D.S.DG.VAP-- I..F..N... ...F...... .......... ..........--   60 
 PtTPT2 .A..SPAEGS- D.S.DG.VAP-- V..FD..... ...F...... .......... ..........--   60 
 RcTPT1 .A..SPAEGS- D.S.DKVAPV-- -..F...... ...F...... .......... ..........--   59 
 RcTPT2 .A.-ADAEGH- ---V.PAA---- KS.G.RF... ...F...... .......... ..V.......--   54 
 StTPT  .A..S.AGSS- D.S.D..V---- -..FN.AT-. T..F...... .......... ..........--   56 
 NtTPT  TA..SPAEGS- D.A.D..V---- -..FN.AT-. I..F...... .......... ..........--   56 
 FpTPT  .T..------- D.A.D.--AP-- V..FA...F. ...F...... .......... ..........--   52 
 FtTPT  .T..------- D.A.D.--AP-- V...A...F. ...F...... .......... ..........--   52 
 TaTPT  .S.EP------ --A....S-P-- -.L......I T..F...... .......... ..........--   51 
 OsTPT1 .-.TS------ ---....PA--- -......... I..F...... .......... ..........--   49 
 OsTPT2 .SS.S--SSL- D.T....PV--- -..A.R.... ...F...... .......... ...FD.....--   56 
 SbTPT  .A.-------- E.A....----- -......... ...F...... .......... ..........--   49 
 SbTPT2 .A..SG----- -.A.D.EP---- Q..A.R..T. ...F...L.. .......... ...FD.....--   53 
 ZmTPT1 .A.E------- -.A....S---- V......... ...F...... .......... ..........--   51 
 ZmTPT2 .A.-------- ---....S---- V......... ...F...... .......... ..........--   48 
 ZmTPT3 .G..SG----- -PA....P---- Q..A.R.... ...F...L.. .......... ...FD.....--   53 
 PsiTPT .GTAD-AEGDE VFISSGLDKPS- QS.AD...W. I..F...... L......... ..........--   61 
 PpTPT  .S..D.SGDDP AEVAKEKKEEA- Q...A..... ...F...A.. ........M. ..........--   62 
 McPPT  .TSV--PES-- AGAD..------ PKAGGIGKT. EL.LL.GF.. LF.IY...Y. .QVLKV.H..--   53 
 VvPPT1 .SSV--PES-- AGES.------- -KSGNLVQT. QL.LL.GL.. LF.IY...Y. .QVLKVY.F.--   51 
 VvPPT2 .SSV--PEN-- AEET.------- -KSSNLGGI. QL..M.AI.. L..IY...F. .Q.LKVY.F.--   51 
 PsPPT  .T----SES-- AAES-------- ADSSSLLKT. QL..L.GL.. LF.IY...Y. .QVLKACHF.--   49 
 GmPPT1 .AE.AVPES-- APVE-------- ---NPLFKT. EL.AL.GL.. LF.IY...Y. .QVLKA.H..--   50 
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 GmPPT2 .AS.I-PDA-- R.DE-----P-- AKTSDFLKTF QL.AM.AT.. L..IYY..Y. .QVLKVY.F.--   53 
 AtPPT1 .ATAV-PES-- AEE.D------- -NSGKLTKV. EL.LL.A... LF.IY...Y. .QVLKALHA.--   52 
 AtPPT2 .T--V-PEN-- VGGD-------- LESGSLVKG. KL.GM.GV.. L..IYY..F. .QVLRVY...--   52 
 BoPPT  .ATAV-PEE-- -GE--------- -.SGKMTKV. EL.LL.A... LF.IY...Y. .QVLKALHA.--   49 
 BnPPT  .ATAV-PEN-- AEE..------- -.SGKMTKV. EL.LL.A... LF.IY...Y. .QVLKALHA.--   52 
 PtPPT1 .T.V--PES-- AGE.DE------ -KSS-LVKT. EL.LL.GL.. LF.IY...Y. .QVLKV..N.--   51 
 PtPPT2 .T.V--PES-- AGE.KE------ -KSS-LTKT. EL.LL.GL.. LF.IY...Y. .QVLRV..N.--   51 
 RcPPT1 .T.V--PES-- AGES.------- -KSSSMIKT. EL.LL.GL.. LF.IY...Y. .QVLKV..N.--   51 
 RcPPT2 .ASV--PES-- T.QN.------- --TSDLARII QLAAM.GI.. L..IYY..F. .QVLKVY.F.--   50 
 NtPPT1 .-T.V-PES-- AGEA-----P-- -KSKPLTDT. .L..L.GL.. LF.IY...Y. .QVLKA.H..--   51 
 NtPPT2 VTS.E.PEI-- SAGE.E--PP-- -KSKPLADT. .L..L.GL.. IF.IY...Y. .QVLKT.H..--   55 
 FtPPT1 .ASV--PDK-- ADDGDAAALG-- -KS-KLVDT. FL..M.GL.. LF.IY...Y. .QVLKVL.S.--  107 
 FtPPT2 DSVVSRAAAS- ETSD.–SANP-- -AE--ISRI. QLAAM.GV.. L..IY...F. .QVLKV....--   56 
 OsPPT1 .ATAA------ AA-...GAEE-- --GGGLAKT. QL.AL.GL.. LF.IY...Y. .QVLKV....--   52 
 OsPPT2 .CGAA------ AGDAK.EE---- -EESGLAKT. QL.AL.GL.. LF.IY...Y. .QVLKV....--   52 
 OsPPT3 .VTARVAAAEA PLPADDADAAAG RERGALAETA QL.AMIVA.. L..IY...Y. .QVLQPL.F.--   63 
 OsPPT4 .AVATAAAAS- PPAEGGGKANGG AVAGGISRTV QL.AMILV.. L..IY...F. .LVLKSV.F.--   62 
 SbPPT1 .A.A.KVAAA- DTA..E------ -AGGGLAKT. QL.AL.GL.. LF.IY...Y. .QVLKVL...--   55 
 SbPPT2 .AGDAVAAPS- ---A.E------ --GGGFMKT. WL..L.GL.. LF.IY...Y. .QVLKV....--   51 
 SbPPT3 .V.AAAAA-S- VPADD.SAAAVT GDRGGIAATA QL.AMIVA.. L..IY...Y. .QVLGAL.L.LP   64 
 SbPPT4 .G.AAAA--S- PPAAGKPE---- -.AAGISRT. QL.AMILV.. L..IY...Y. .LVLKAI.F.--   55 
 ZmPPT1 .ASA------- GEE--------- -AGGGLAKT. QL.AL.GL.. LF.IY...Y. .QVLKVL...--   46 
 ZmPPT2 .A.D.A----- VEE--------- -AGGGLVKT. QL..L.GL.. LF.IY...Y. .QVLKVL...--   48 
 ZmPPT3 .AGDAVAAPK- AEE--------- --GGGLMKT. WL..L.GL.. LF.IY.H.Y. .QVLKV....--   51 
 PpPPT                                LAET. QL..L.GL.. MF.IC...Y. .QVLKV....--  
 McGPT1 .YEAD-GSEP- -IKP.PVPVP-- -IPG.AARKV KI.IY.AV.W A...V...Y. ..VL.A....--   57 
 McGPT2 .YEANRSQPLD -INI.L---P-- SVKS.TAKRV KI.IY.AT.W A...V...Y. ..VL.A....--   57 
 VvGPT1 .YEAE-RSQPL DLNI.LS-DQ-- EARS.AAQK. KI.IY.AT.W A...V...Y. ..VL.A....--   59 
 VvGPT2 .YEAD-RSEP- VES-DVVK---- -.RS.AAKKV KI.LY.AT.W A...V...Y. ..VL.A....--   55 
 PsGPT  .YEAD------ --RS.VEGGD-- GTPS.AAKKV KI.IY.AT.W A...V...Y. ..VL.AY...--   53 
 GmGPT  .YEAD------ --RS.VEGA--- STPS.AAKKV KI.IY.AT.W A...V...Y. ..VL.AY...--   52 
 MtGPT  .YEADRSQPLE -INIDIAGEQ-- -----AAQK. KI.LY.AT.W A...V...Y. ..VL.A....--   55 
 AtGPT1 .YEAD-RSEP- HPIGDDAAAA-- ETKS.AAKK. KI.IY.AT.W A...V...Y. ..VL.AY...--   59 
 AtGPT2 .YEAD-RSRP- LDI-NIEL-P-- DEQSAQ--K. KI.IY.AT.W A...V...Y. ..VL.A....--   54 
 ThGPT  .YEAD-RSQPI EIGI.IS----- DEQSRQ--KV KI.IY.AT.W A...V...Y. ..VL.A....--   54 
 StGPT  .YEASQPQ--- SIPIDIEFGQ-- EAQAAATQK. KI.LY.AT.W A...V...Y. ..VL.A..F.--   58 
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 HaGPT  .YEA------- --GGDVV----- -ENT.AAKRV KI.FY.AT.W ......X.Y. ..VL.A....--   48 
 TaGPT  .S.AD----DK E.KA.VLPA--- --SS.AAQK. KISIY.AT.W A.......Y. ..VL.A....--   54 
 OsGPT1 .S.AD----DK E.KT.VVPV--- --RS.AAQK. KISIY.AT.W A.......Y. ..VL.A....--   55 
 OsGPT2 SATAD-GARP- VEAAP.GAAP-- ---E.AARRA KI.VY.AT.W A.......Y. ..VL.A....--   57 
 SbGPT  .S.AD----DK E.KTK.VPV--- --QS.GAQR. KISIY.AT.W A.......Y. ..VL.A....--   54 
 ZmGPT  .S.AD----DK E.KTQVVPV--- --QS.GAQR. KISIY.AT.W A.......Y. ..VL.A....--   54 
 PsiGPT .YEAS.SDLVS D.DV.EEVLSEN PSPQAAAQR. KI.IY.VA.W T...V...Y. ..VL.A....--   63 
 PpGPT  .YPE.---TPK VGDV.------- -VPKPAMRRV KI.IY.AT.W A...V...Y. ..VL.V..F.--   52 
 VvXPT  VAKAA------ ----.FEGES-- EVS-KPNKT. QL.IV.G... .Q.IV...Y. ..VL.L..F.--   50 
 GmXPT  IVKAA------ -SEANPEGENV- APTEPNSKN. KL.LV.GL.. .Q.IV...Y. ..VL.I..F.--   55 
 AtXPT  .AV-..SDSN- PDEKSDLGEA-- EKKEKKAKT. QL.IV.GL.. .Q.IV...F. ..AL.V....--   59 
 GsTPT2 AAV---DKSE- SGGSPQKSSV-- GVSPTLVHT. KV.FY.FL.. .F.F....A. .RTL.MWK..--    
 PfoTPT TFPITINEGYS DNVGDNKLKSK- GIYHKLFEK. KLALL.LT.. T...LY.VD. ..AL.MVKL.-- 
 TgAPT  QYGTVSTGGAR PAKDLESQASP  ASGDQTAFYA QL.VMLLF.. A...MY.LD. .LALIML.L.--  
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 SoTPT  YFVSVIHLFV GVVYCLASWS VGLPKRAPMD -----SKLLKLLIPV AVCHAIGHVT SNVSFAAVAV  110 
 McTPT  ........L. ..I...V..A ........I. -----GN........ .L...L.... ..........  113 
 VvTPT  .......... ......V..G ........I. -----.N........ .....L.... ..........  117 
 VvTPT2 R..AF...L. ..I...VC.. L.......I. -----KEF.L..T.. .F...L...M T.....S...  114 
 VvTPT3 ....L...L. ..A...V..A .......... -----KE..L..T.. .L...L...M ..........  114 
 PsTPT  ........A. ......V..T ........I. -----GN........ .....L.... ..........  116 
 AtTPT  .......... ......I... ........I. -----.N...V.... .....L.... ..........  114 
 BoTPT  .......... ......V... ........VN -----.DI..V.... .......... ..........  114 
 PtTPT1 .......... ......V..T ........I. -----.N..K..... .....L.... ..........  120 
 PtTPT2 .......... ......V..A .......... -----.N........ .....L.... ..........  120 
 RcTPT1 ........L. ......V..A ........I. -----.N........ .....L.... ..........  119 
 RcTPT2 ........L. ......T..G F.......I. -----RD..V..T.. .C...L...M ..........  114 
 StTPT  ........A. ......V..T ........I. -----.TQ....T.. .F...L.... ........R.  116 
 NtTPT  ........A. ......I..T ........I. -----.TQ....T.. .F...L.... ..........  116 
 FpTPT  ....A...A. ......GG.A .......... -----.N........ .F...L.... ..........  112 
 FtTPT  ........A. ......G..T ........V. -----.NI....... GF...L.... ..........  112 
 TaTPT  ........L. ......L..A ........IN -----AT.....F.. .L...L.... ......T...  111 
 OsTPT1 ........L. ......L..A ........IN -----ST.....F.. .L...L..A. ......T...  109 
 OsTPT2 .....S..L. ..L...VG.. F.......IN -----.TV....F.. .......... .T........  116 
 SbTPT  ....L...V. ..A...VG.. ........IN -----AN.....F.. .L..G..... ..........  109 
 SbTPT2 .....S...I ..L...IG.. F.I.....IN -----.T...Q.L.. .......... .T........  113 
 ZmTPT1 ....L...V. ......I... ........IN -----GT.....F.. .L..G...I. ..........  111 
 ZmTPT2 ....L...V. ......I... ........IN -----GT.....F.. .L..G...I. ..........  108 
 ZmTPT3 .....S...I ..L...IG.. F.I.....IN -----.T...QLV.. .......... .T........  113 
 PsiTPT ........V. ..A...V... L.......I. -----KE..L..T.. .I...L...M T.....T...  121 
 PpTPT  ....A...A. ......I..M L.Y.....I. -----KE.FMM.... SI...L...M T.........  122 
 McPPT  VT.T..QFA. .S.LVGLM.L FN.Y..PKIS -----MGQ.AAIL.L ..V.TL.NLF T.M.LGK...  113 
 VvPPT1 VT.T.VQFA. .T.LVILM.G LN.Y..PKIS -----.SQ.VAIL.L ..V.TL.NLF T.M.LGK.S.  111 
 VvPPT2 AT.TAFQFGC .T.LVILM.A FN.Y..PKIS -----KSQFSGILIL ..T.TM.NLL T.L.LRK...  111 
 PsPPT  VT.T.VQFA. .T.LVSVM.A LN.Y..PKIN -----GAM.AAIF.L .IV.TL.NLF T.M.LGK...  109 
 GmPPT1 VT.T.VQFA. .T.LVAFM.G LN.Y..PKLS -----GAM.GAIL.L .AV.TL.NLF T.M.LGK...  110 
 GmPPT2 ATITAFQFGF ASLVINLV.T LN.HP.PSIS -----GSQFAAIL.L ..A.TM.NLL T.I.LGK...  113 
 AtPPT1 MT.TLVQFA. .S.LITIM.V LN.Y..PKIS -----GAQ.AAIL.L ..V.TL.NLF T.M.IGK.S.  112 
 AtPPT2 AT.TAFQ.GC .TLMIAIM.L LK.HP.PKFS -----PSQFTVIVQL ..A.TL.NLL T...LGR.N.  112 
 BoPPT  MT.TLVQFA. .S.LITFM.A LN.Y..PKIS -----AAQ.AAIL.L ..V.TL.NLF T.M.LGK.S.  109 
 BnPPT  MT.TLVQFA. .S.LITFM.A LN.Y..PKIS -----AAQ.AAIL.L ..V.TL.NLF T.M.LGK.S.  112 
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 PtPPT1 VT.TAVQFA. .T.LVVFM.T FN.Y.KPKIS -----GAQ.AMIL.L ..V.TL.NLF T.M.LGK...  111 
 PtPPT2 VTITAAQFT. .T.LVACM.T FN.Y.KPKVS -----GAQ.AAIL.L ..V.TL.NLF T.M.LGK...  111 
 RcPPT1 VTITLAQFA. .T.LVTLM.T FN.Y..PKIT -----LAQ.AAIL.L .FV.TL.NLF T.M.LGK...  111 
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 VvGPT1 ...LA.VF.N IF..RG.K-GK ------SVGGM-.Y.. CL.MLS.LIL ---T.F..A. ....MWAA.W QK..SQ---  241 
 VvGPT2 ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL..MS.LIL ---T.F..A. ....MWAA.W QN.VSQ---  237 
 PsGPT  ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL..LS.AIL ---T.F..A. ...AMWAA.W QT.LSE---  235 
 GmGPT  ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL..LS.AIL ---T.F..A. ....MWAA.W QT.MSQ---  234 
 MtGPT  ....A.VF.N IF...G.K-G. ------SV.GM-.Y.. CL..LS.LLL ---T.F..A. ...TMWAA.W QT.------  237 
 AtGPT1 ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL.MLS.LIL ---T.F..A. ....MWVD.W QT.L.T---  241 
 AtGPT2 ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL.MMS.VIL ---T.FS.A. ....MWAA.W QN.VSQ---  236 
 ThGPT  ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL.MMS.LIV ---T.F..A. ....VWAA.W QN.VSE---  236 
 StGPT  ...LA.VF.N IF...G.K-GK ------SVGGM-.Y.. CL.MMS.LIL ---I.F..A. ....VWAL.W QN.VSQ---  240 
 HaGPT  ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL.MLS.LIL ---T.F..A. ...KMWAA.W QN.VTE---  230 
 TaGPT  ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL..MS.VIL ---T.FA.AM ....MWAA.W QK.L.D---  236 
 OsGPT1 ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL..MS.VIL ---T.FA.AM ....MWAA.W QK.L.E---  237 
 OsGPT2 ...LA.VF.N IF...G.K-GK ------SV.GM-.Y.. CL.MLS.VIL ---L.FAFAM ...KVWAA.W QK.VAE---  239 
 SbGPT  ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL..MS.VIL ---T.F..AM ....MWAA.W QK.L.E---  236 
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 ZmGPT  ...LA.VF.N IF..RG.K-GK ------SV.GM-.Y.. CL..MS.VIL ---T.FA.AM ....MWAA.W QK.L.E---  236 
 PsiGPT ...LA.VF.N IF...G.KAGK ------SVGGM-.Y.. CL.MMS.ALL ---T.F.FA. ....AWAA.W QE.LRA---  246 
 PpGPT  V..IA.VF.N IF...G..SGK ------SVGGM-.Y.. CL.MMS.VFL ---T.F..A. ...KSWTA.W DA.NLT---  235 
 VvXPT  ...VG.VL.N IY..RSLE-SF ------KEVNGL.L.G W....S.LYL ---F.VA.F. ..T.-WIE.Y HR..QA---  232 
 GmXPT  ...VG.VL.N IY..RSLQ-NF ------KEVDGL.L.G W.T.LS.LYL ---F.V..F. ..S.-WIP.Y YK..EA---  236 
 AtXPT  ....G.VL.N I...RSLQ-SF ------KEIDGL.L.G C...LS.LYL ---F.VA.F. ..SH-WVP.Y HK...S---  240 
 GsTPT2  ....A.VT.N IT..FT.V-DF KNEKTL-IAQ--.T.. L.T..SF.ME ---..F.LLM ..F----PPL VS...G--- 
 PfoTPT L..FGSSI.. I.A..M..-QK SLIGENLNAS--.... F.T..SALIS ---..LVLAF ..KETYNFLV .YQGTN--- 
 TgAPT  V.ALGSSA.A VFA.L..A-.R KQVGENLS.A--.M.. LLT.V.SL.S ---..L..FA ..AKVAAV-W EACTGPDSP 
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        _ _ _ _________ __VI__________ _ _ _                         
 
 SoTPT  VG-LTKFISDL FWVGMFYHLY NQLATNTLER VAPLTHAVGN VLKRVFVIGF SIIAFGNKIS  290 
 McTPT  ..-.....T.. .......... .......... .......... .......... ...I......  293 
 VvTPT  ..-....L... .......... .......... .......... .......... ..LV......  297 
 VvTPT2 ..-.A.LV... ....L.F..D ....VS.... .S.......S .....V..VL .T.V.....T  294 
 VvTPT3 ..-....L... ..I....... .......... .......... .......... ..VI......  294 
 PsTPT  ..-.V..V... .......... ..V....... .......... .......... ...I......  296 
 AtTPT  ..-M....... .......... .......... .......... .......... ..VI......  294 
 BoTPT  ..-M....... .......... ..L....... .......... .......... ..VI......  294 
 PtTPT1 ..-........ .......... .......... .......... .......... ..LI......  300 
 PtTPT2 ..-........ .......... .......... .......... .......... ..VI......  300 
 RcTPT1 ..-T....T.. .......... .......... .......... .......... ..VV......  299 
 RcTPT2 ..-.F..V... ..I....... ..V....... .......... .......... ..VV...R..  294 
 StTPT  ..-....VT.. .......... ..V....... .......... .......... ..VI......  296 
 NtTPT  ..-....VT.. .......... ..V....... .......... .......... ...V......  296 
 FpTPT  ..-M....... .......... ....I..... .......... .......... ...V......  292 
 FtTPT  ..-MI...... .......... ..I....... .......... .......... ...V......  292 
 TaTPT  ..-M...V... .L..L..... ..I....... .......... .......... ...I.....T  291 
 OsTPT1 ..-M...V... .L..L..... ..I....... .......... .......... ...V...R.T  289 
 OsTPT2 ..-.A.LV.N. LV..L..... ..V....... .T........ .......... .........T  296 
 SbTPT  ..-....V... VL..L..... ..I....... .......... .......... ..VV......  289 
 SbTPT2 ..-...L..NF .V..L..... ..V....... ....S..I.. .......... ...V.....T  293 
 ZmTPT1 ..-....V... .L..L..... ..I....... .......... .......... ...V......  291 
 ZmTPT2 ..-....V... .L..L..... ..I....... .......... .......... ..VV......  288 
 ZmTPT3 ..-...L..NF .V..L..... ..V....... .......I.. .......... .........T  293 
 PsiTPT ..-.V..L... .......... .......... .......... .......... ...V...R..  301 
 PpTPT  ..-MQ..L... .......... ....N..... .......... .......... ..VV......  302 
 McPPT  LN-VQQVYMKS .LAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .V.V.RTAVN  298 
 VvPPT1 LN-MGQIYKRS LIAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VT .VLF.RTPV.  293 
 VvPPT2 LN-VRELCVRS LLA.ICF.S. Q.VSYTI.QM .S.V..A... CV...V..IS .V.F.QTPA.  296 
 PsPPT  LN-VRQVYTRS LLAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .V.I.KTPV.  291 
 GmPPT1 .N-VRQLYIRS LLAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .V.F.QTPV.  293 
 GmPPT2 LN-VRELCVRS VLAAFCF.A. Q.VSHMI.QM .S.V..S... CV...V..VS .V.F.QIPV.  298 
 AtPPT1 .N-VKQIYTKS LIAALCF.A. Q.VSYMI.A. .S.V..S... CV...V..VS .V.F.KTPV.  294 
 AtPPT2 LS-VKE.CIMS LLA.VCL.S. Q.VSYMI..M .S.V..S... CV...V..TS ..LF.KTPV.  293 
 BoPPT  .N-VQQIYTKS LIAALCF.A. Q.VSYMI.A. .S.V..S... CV...V..VS .V.F.KTPV.  291 
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 BnPPT  .N-VQQIYTKS LIAALCF.A. Q.VSYMI.A. .S.V..S... CV...V..VS .V.F.KTPV.  294 
 PtPPT1 LN-VKQVYTRS LIAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .VFF.KTPV.  293 
 PtPPT2 LN-VKEVYTRA .LAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .VLF.KTPV.  293 
 RcPPT1 LN-VKEVYIRS LLAALCF.A. Q.VSYMI.Q. .S.V..S... CV...V..VS .VLF.RTPV.  293 
 RcPPT2 LN-VRELCVRA LIA.FCF.S. Q.VSYLI.QM .N.VS.A... SV...V..VS .V.F.QIP..  295 
 NtPPT1 .N-VNQLYTRS LIAALCF.A. Q.VSYMI.Q. .S.V..SL.. CV...V..VT .VLF.RTPV.  293 
 NtPPT2 LN-VNQIYTRS LLAALCF.A. Q.VSYMI... .S.V..S... CV...V..VT .VLF.RTPV.  297 
 FtPPT1 LN-VQQIYVRS LLAAICF.A. Q.VSYMI.Q. .S.V..S... CV...V..VT .VLF.RTPV.  349 
 FtPPT2 .N-VRELCVRA LLT.ICF.S. Q.VSYMI..M .S.V....A. CV...V..VS .V.F.RTPVT  301 
 OsPPT1 LN-.KQIYTRS LIAAFCF.A. Q.VSYMI.A. .S.V..S... CV...V..VT .VLF.RTPV.  294 
 OsPPT2 LN-VKQVLTRS LLAALCF.A. Q.VSYMI.A. .S.V..S... CV...V..VT .VLF.RTPV.  294 
 OsPPT3 LN-.QELCVRA ALA.FCF.G. QK.SYLI.A. .S.V..S.A. CV...V..VA .VLF.RTP..  305 
 OsPPT4 .N-.QELCMKA ALA.TCF.F. Q.VSYSL.A. .S.V..S.A. CV...V..VS .VLF.RTP..  304 
 SbPPT1 LN-.KQVYTRS LIAAFCF.A. Q.VSYMI.A. .S.V..S... CV...V..VT .VLF.RTPV.  297 
 SbPPT2 LN-VNQVLTRS LLA.LCF.A. Q.VSYMI.AM .S.V..S... CV...V..VT .VLF.RTPV.  293 
 SbPPT3 LN-.QELCVRA ALA.LCF.G. QK.SYLI.S. .S.V..S.A. CV...V..VS .VLF.STP..  305 
 SbPPT4 .S-VKELCVRA ALA.TCFYF. Q.VSYSL.A. .S.V..S.A. SL...V..VS .VLF.RTP..  297 
 ZmPPT1 LN-.KQVYTRS LIAACCF.A. Q.VSYMI.A. .S.V..S... CV...V..VT .VLF.RTPV.  288 
 ZmPPT2 LN-.KQIYTRS LIAACCF.A. Q.VSYMI.A. .S.V..S... CV...V..VT .VLF.RTPV.  290 
 ZmPPT3 LN-VNQVLTRC LFA.LCF.A. Q.VSYMI.AM .S.V..S... CV...V..VT .VLF.RTPV.  293 
 PpPPT  LD-VKVVVTRA LIA.LCF.A. Q.VSYMI.AK .T.V..S... CV...V..VT .VLF.RTPV. 
 McGPT1 I.-S-N..WW. TAQSV..... ..VSYMS.DE IS...FSI.. TM..IS..VS ...I.RTPVQ  298 
 McGPT2 I.-P-N.VWWV AAQSI..... ..VSYMS.DQ IS...FS... TM..IS..VS ...I.HTP.Q  298 
 VvGPT1 I.-P-N..WWV AAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.HTPVQ  300 
 VvGPT2 I.-P-H.VWWV AAQSV..... ..VSYMS.DE IS...FSI.. TM..IS..VS ...I.HTPVQ  296 
 PsGPT  I.-P-Q..WWV AAQSI..... ..VSYMS.DE IS...FSI.. TM..IS..VS ...I.HTP.Q  294 
 GmGPT  I.-P-Q..WW. AAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.HTPVQ  293 
 MtGPT  -------NWWV AAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.HTP.Q  296 
 AtGPT1 ..-P-Q.VWWV VAQSV..... ..VSYMS.DQ IS...FS... TM..IS..VS ...I.RTPVQ  300 
 AtGPT2 ..-P-N.VWWV VAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VA ...I.HTP.Q  295 
 ThGPT  I.-P-N.VWWV AAQSV..... ..VSYMS.DQ IS...FS... TM..IS..VA ...I.HTP.R  295 
 StGPT  I.-P-N..WWV VAQSV..... ..VSYMS.NE IS...FSI.. TM..IS..VS ...I.QIPIQ  299 
 HaGPT  I.-P-H..WWV AAQSI..... ..VSYMS.DE IS...FSI.. TM..IS..VS ...I.HTPVQ  289 
 TaGPT  ..-P-NVLWWI GAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.RTPVR  295 
 OsGPT1 ..-P-DVVWWV AAQSV..... ..VSYMS.DE IS...FSI.. TM..IS..VS ...I.HTPVR  296 
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 OsGPT2 I.-P-N.VWWV AAQSV..... ..VSYMS.DE IS...FSI.. TM..IS..VA ...I.HTPVQ  298 
 SbGPT  ..-P-NV.WWI AAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.HTPVR  295 
 ZmGPT  ..-P-NVVWWI AAQSV..... ..VSYMS.DQ IS...FSI.. TM..IS..VS ...I.HTPVR  295 
 PsiGPT I.-P-Q.VWWV AAQSV..... ..VSYMS.NE IS...FSI.. TM...S...S ...I.RTEVR  305 
 PpGPT  ..-P-.IFWWV VAQSV..... ..VSYMS.NE IS...FSI.. TM...T..VS ...I.HTQVQ  294 
 VvXPT  ..KP.T.YIWV MLS.V..... ..SSYQA.DD IS...FS... TM...V..VA T.LV.R.PVK  293 
 GmXPT  I.KAST.YTWV LVS.V..... ..SSYQA.DE IS...FS... TM...V..VS .VLV.R.PVR  297 
 AtXPT  ..TPST.YFWV LLS.V..... ..SSYQA.DE IS...FS... TM...V..IS TVLV.R.PVR  301 
 GsTPT2  .S-KA.LFGSI MFCSL..... .EVSYLC.DN .S.VSFSI.. TI...II.FG ..LV.RTPVT 
 PfoTPT YT-FKDV.FKI ILS..W.YFN .EV.FMC... .NQI...LA. SI...VI.VS ...I.KTQ.T 
 TgAPT  WT-GQQI.AK. CFS.LW.YM. .EV.YLC..K INQV....A. T....VI.VA .VLF.QTPVT  
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 SoTPT  TQTAIGTSIA IAGVALYSLI KAKMEEEKRQ -----MKST  324 
 McTPT  .......... .....I..F. .G........ -----K.AA  327 
 VvTPT  ...G...CV. .....M..F. .......... -----L..A  331 
 VvTPT2 .......A.. .T...I.... R.N....NQN -----AAA.  328 
 VvTPT3 R..G...A.. .....I.... ..NI..Q..K --AAVTPAS  331 
 PsTPT  ...G...G.. ........F. ..QI...... -----A.AA  330 
 AtTPT  ...G...G.. .....CT.I. ...I...... -----G.KA  328 
 BoTPT  ...G...G.. ........V. ...I...... -----G.TA  328 
 PtTPT1 ...G...G.. .....T..Y. .........R -----G.AA  334 
 PtTPT2 ...G...AV. .....T..Y. ...L...... -----G.AA  334 
 RcTPT1 ...G...C.. .....M..FL ...I...... -----G.TA  333 
 RcTPT2 ...G...A.. .....M.... ..N...Q..K --AAIAPAS  328 
 StTPT  ...G...C.. .....I..F. .......... -----K.AA  330 
 NtTPT  ...G...C.. ........F. .......... -----K.AA  330 
 FpTPT  .......... .....V.... ...I.....G -----L..A  326 
 FtTPT  .......... .....I.... ..RI.....R -----...A  326 
 TaTPT  ...G...CV. ........Y. ...I.....- -----A.AA  325 
 OsTPT1 ...G...C.. ........Y. ...I.....- -----A..A  323 
 OsTPT2 ...G...C.. ........Y. ...I....T. -----...A  330 
 SbTPT  ...G...... ........Y. ...I.....- -----K..A  322 
 SbTPT2 ...G...... .S......F. ...I....K. -----I..A  327 
 ZmTPT1 ...G...... .....M..Y. ...I.....- -----K..A  325 
 ZmTPT2 ...G...... .....M..Y. ...I.....- -----K..A  322 
 ZmTTP3 ...G...... VS......F. ...I..-.K. -----I..A  326 
 PsiTPT .......... .....I..F. ..QL.....K AVPPSPRAS  340 
 PpTPT  ...G...A.. .G......F. ..RQ..A.IA -----K.AA  336 
 McPPT  PIN.L..AV. L...F...-- RV.R--I.AK -----A.EA  328 
 VvPPT1 PVNSL..GV. L...F...-- RV.R--I.-- -----P.TA  321 
 VvPPT2 PINSL..GV. LV..F...-- R..R--M.PK -----P.AA  326 
 PsPPT  PVN.L..AVG L...F...-- RV.R--I.SK -----P.AV  321 
 GmPPT1 PVN.F..A.. L...F...-- RV.R--I.AK -----P.TA  323 
 GmPPT2 PVNTL..GL. LV..F...-- R..R--I.SV -----Q.TN  328 
 AtPPT1 PVN.F..G.. L...F...-- RV.G--I.PK -----P.TA  324 
 AtPPT2 PLNS...AT. L...Y...-- R..RVQV.PN -----P.MS  325 
 BoPPT  PVN.F..G.. L...F...-- RV.R--I.PK -----P.TA  321 
 BnPPT  PVN.F..G.. L...F...-- RV.R--I.PK -----P.TA  324 
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 PtPPT1 PINSL..GV. L...F...-- RV.R--I.PK -----P.TA  323 
 PtPPT2 PINSL..G.. L...F...-- RV.S--I.PK -----P.TA  323 
 RcPPT1 PINSL..G.. L...F...-- RV.R--I.PK -----P.TA  323 
 RcPPT2 PVNSL..A.. L...F...-- R..R---.TP --PPMP.AS  327 
 NtPPT1 PINGL..GV. L...F...-- RV.R--I.PK -----A.TE  323 
 NtPPT2 PINT...GV. L...F...-- RV.G--I.PK -----P.TA  327 
 FtPPT1 PINS...GV. L...F...-- QV.R--L.-- -----P.KA  377 
 FtPPT2 PIN.L..GL. L...F...-- R..R--I.-- -----P.AA  329 
 OsPPT1 PINSL..GV. L...F...-- QL.R--L.PK -----P.TA  324 
 OsPPT2 PINSL..A.. L...F...-- QL.R--L.PK -----P.AA  324 
 OsPPT3 PVN.L..GV. LG..F...-- RL.R--T.-- -----P.NA  333 
 OsPPT4 PIN.L..GV. L...F...-- RF.K--A.PK -----A.TA  334 
 SbPPT1 PINSL..G.. L...F...-- QL.R--L.PK -----P.AA  327 
 SbPPT2 PINSL..A.. L...F...-- QL.R--L.PK -----P.TP  323 
 SbPPT3 PVN.L..GA. L...F...-- RLTR--T.-K -----P.DA  334 
 SbPPT4 PIN.L..GV. L...F...-- QF.K--L.PK -----T.AA  327 
 ZmPPT1 PINSL..G.. L...F...-- QL.R--L.PK -----P.TA  318 
 ZmPPT2 PINSL..G.. L...F...-- QL.R--L.PK -----P.AA  320 
 ZmPPT3 PINSL..A.. L...F...-- QL.R--L.PK -----P.TA  323 
 PpPPT  PVNGL..GL. LC.VFA..-- RV-----.SK ------.-- 
 McGPT1 PVN.L.AA.. VF.TF...-- ---------. -----A.Q-  320 
 McGPT2 PVN.L.AA.. .L.TFI..-- ---------. -----A.V-  320 
 VvGPT1 PVN.L.AA.. .L.TK???-- --???????? -----????  3?? 
 VvGPT2 PIN.L.AA.. .L.TF...QV ?????????? -----????  3?? 
 PsGPT  PVN.L.AA.. VF.TF...-- ---------. -----A.Q-  316 
 GmGPT  PIN.L.AA.. .L.TF...-- Q..G-.VRLN -----LQD-  323 
 MtGPT  PNN.L.AA.. .L.TF...-- ---------. -----A.Q-  318 
 AtGPT1 PVN.L.AA.. .L.TF...-- ---------. -----A.L-  322 
 AtGPT2 PVN.L.AA.. .F.TF...-- ---------. -----A.Q-  317 
 ThGPT  PVN.L.AA.. .L.TFI.F-- ---------. -----VE--  316 
 StGPT  PIN.L.AA.. .L.TF...-- ---------. -----A.Q-  321 
 HaGPT  PIN.L.AA.. .F.TF...-- ---------. -----A.Q-  311 
 TaGPT  PVN.L.AA.. .F.TF...-- ---------. -----A.Q-  317 
 OsGPT  PVN.L.AA.. .L.TF...-- ---------. -----A.Q-  318 
 OsGPT2 PIN.L.AA.. .L.TFI..-- ---------. -----A.Q-  320 
 SbGPT  PVN.L.AA.. .L.TF...-- ---------. -----A.A-  317 
 ZmGPT  AVN.L.AA.. .L.TF...-- ---------. -----A.A-  317 
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 PsiGPT PVNGL.AA.. .L.TF...-- ---------. -----A.Q-  316 
 PpGPT  PMN.V.AA.. .F.TF...QV LHHALPYFLA -RTELL.--  330 
 VvXPT  PLN.L.SA.. .F.TF...QA TS.KSPK.IE ----GEKSS  328 
 GmXPT  PLNGL.SA.. .L.TF...QA TS.------- -----K.A-  323 
 AtXPT  PLN.L.SA.. .C.TF...QA TA.KKKIEVG ----GD.KN  336 
 GsTPT2 RLNF..ST.. .I.TM....A ...LPS-..E ------.Q- 
 pfoTPT LLG...SAV. .F.AF...IF ---------- --------- 
 TgAPT  ALG.T.SFV. ...TLI...S ---------K -----T.YG  
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So Spinacia oleracea (Caryophyllales, Amaranthaceae) 
Mc Mesembryanthemum crystallinum (Caryophyllales, Aizoaceae) 
Cs Camellia sinensis (Ericales, Theaceae) 
Fp Flaveria pringlii (Asterales, Asteraceae) 
Ft Flaveria trinervia (Asterales, Asteraceae) 
Ha Helianthus annuus (Asterales, Asteraceae) 
St Solanum tuberosum (Solanales, Solanaceae) 
Nt Nicotiana tabacum (Solanales, Solanaceae) 
Bo Brassica oleracea (Brassicales, Brassicaceae) 
Bn Brassica napus (Brassicales, Brassicaceae) 
At Arabidopsis thaliana (Brassicales, Brassicaceae) 
Pt Populus trichocarpa (Malpighiales, Salicaceae) 
Rc Ricinus communis (Malpighiales, Euphorbiaceae) 
Ps Pisum sativum (Fabales, Fabaceae) 
Gm Glycine max (Fabales, Fabaceae) 
Mt Medicago trunculata (Fabales, Fabaceae) 
Vv Vitis vinifera (Vitales, Vitaceae) 
Zm Zea mays 
Os Oriza sativa 
Ta Triticum aestivum 
Sb Sorghum bicolor 
Psi Picea sitchensis 
Pp Physcomitrella patens 
Th Thelungiella halophila 
 
 
Gs Galderia sulphuraria 
Pf Plasmodium falciparum 
Tg Toxoplasma gondii 
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Appendix 2: Sequence alignment between PfoTPT and GsTPT2 during 
homology modelling 
 
 
 
